

Publikationen

1. Naphtho[2,3-c]pyrane und Benz[g]isochinoline aus 6-Methoxy-2H-pyran-3(6H)-on.
F. Eiden, B. Wünsch, *Arch. Pharm. (Weinheim)* **1986**, 319, 886 - 889. DOI 0365-6233/86/1010-0886.
2. 6-Methoxy-2H-pyran-3(6H)-on als Baustein zur Synthese von Pyrano-chinolinen, -chinazolinen und -benzodiazepinen.
F. Eiden, B. Wünsch, *Arch. Pharm. (Weinheim)* **1987**, 320, 813 - 822. DOI 0365-6233/87/0909-813.
3. Synthese und Struktur von Tetrahydropyrano[2,3-b]-[1,4]dioxinen.
F. Eiden, B. Wünsch, *Arch. Pharm. (Weinheim)* **1990**, 323, 63 - 65. DOI 0365-6233/90/0202-0063.
4. 5,6-Dihydro-6-methoxy-2H-pyran-3(4H)-on, Baustein zur Synthese von ZNS-Wirkstoffen.
F. Eiden, B. Wünsch, *Arch. Pharm. (Weinheim)* **1990**, 323, 393 - 399. DOI 0365-6233/90/0707-0393.
5. Synthese und ZNS-Wirkungen von cis-Pyrano[2,3-b]-[1,4]dioxanderivaten.
F. Eiden, B. Wünsch, J. Schünemann, *Arch. Pharm. (Weinheim)* **1990**, 323, 481 - 486. DOI 0365-6233/90/0808-0481.
6. Eine neue Methode zur Darstellung von 3-Alkoxy- und 3-Hydroxy-3,4-dihydro-1H-2-benzopyranen.
B. Wünsch, *Arch. Pharm. (Weinheim)* **1990**, 323, 493 - 499. DOI 0365-6233/90/0808-0493.
7. ZNS-Wirkstoffe: Synthese von Epoxybenzoxocinen.
B. Wünsch, *Arch. Pharm. (Weinheim)* **1990**, 323, 933 - 936. DOI 0365-6233/90/1111-0933.
8. A new heterocycle with analgesic activity: 2,6-epoxy-1,2,3,4,5,6-hexahydro-3-methyl-3-benzazocine.
B. Wünsch, G. Höfner, G. Bauschke, *Heterocycles* **1990**, 31, 1427 - 1429.
9. 2,6-Epoxy-3-benzoxocin-4-ol-Derivate durch zweifache intramolekulare Halbacetalbildung.
B. Wünsch, G. Bauschke, *Liebigs Ann. Chem.* **1991**, 59 - 65. DOI 0170-2041/91/0101-59.
10. Synthese und zentrale Wirkungen von 4-hydroxy-(alkyl)- und 4-amino-(alkyl)-substituierten 2,6-Epoxy-3-benzoxocinen.
B. Wünsch, G. Bauschke, *Arch. Pharm. (Weinheim)* **1991**, 324, 867 - 873. DOI 0365-6233/91/1111-0867.

11. Chirale 2-Benzopyran-3-carbonsäure-Derivate durch Oxa-Pictet-Spengler-Reaktion von (S)-3-Phenylmilchsäure-Derivaten.
B. Wunsch, M. Zott, *Liebigs Ann. Chem.* **1992**, 39 - 45. DOI 0170-2041/92/0101-0039.
12. Synthesen und Umsetzungen von 2,6-Epoxy-4H-3-benzoxocin-4-onen.
B. Wunsch, G. Bauschke, *Liebigs Ann. Chem.* **1992**, 345 - 350. DOI 0170-2041/92/0404-0345.
13. Synthese enantiomerenreiner 6,10-Epoxybenzocycloocten-7-amine mit ZNS-Aktivität.
B. Wunsch, M. Zott, G. Höfner, *Arch. Pharm. (Weinheim)* **1992**, 325, 733 - 739. DOI 0365-6233/92/1111-0733.
14. A facile, high yielding synthesis of homophthalaldehyde.
B. Wunsch, M. Zott, *Synthesis* **1992**, 927 - 928.
15. [3+5]-Anellierung mit Homophthalaldehyd: Schlüsselreaktion zur Gewinnung zentral wirksamer Tricyclen.
B. Wunsch, M. Zott, G. Höfner, *Liebigs Ann. Chem.* **1992**, 1225 - 1230. DOI 0170-2041/92/1212-1225.
16. Stereoselektive Synthese neuer zentral wirksamer Tricyclen vom Benzomorphan-Typ mit 2-Phenylethylamin-Partialstruktur.
B. Wunsch, G. Höfner, G. Bauschke, *Arch. Pharm. (Weinheim)* **1993**, 326, 101 - 113. DOI 0365-6233/93/0202-0101.
17. 2,6-Epoxy-3-benzazocine: Zentral wirksame N/O-Acetale durch Ringschluß von Amino- und Amidoacetalen.
B. Wunsch, G. Höfner, G. Bauschke, *Arch. Pharm. (Weinheim)* **1993**, 326, 127 - 133. DOI 0365-6233/93/0303-0127.
18. Benzomorphan-Analoga mit Doxpicomin Partialstruktur: Synthese und psychopharmakologische Untersuchung von 5-Aminomethyl und 5-(α -Aminobenzyl) substituierten 2,6-Epoxy-3-benzoxocinen.
B. Wunsch, G. Bauschke, *Arch. Pharm. (Weinheim)* **1993**, 326, 171 - 180. DOI 0365-6233/93/0303-0171.
19. Synthese und ZNS-Aktivität spirocyclischer Pethidin- und Prodin-Analoga.
B. Wunsch, G. Höfner, G. Bauschke, *Arch. Pharm. (Weinheim)* **1993**, 326, 513 - 518. DOI 0365-6233/93/0909-0513.
20. Synthese homochiraler 5,9-Epoxybenzocyclooctene mit Aminosubstituenten: Zusammenhang zwischen Struktur und ZNS-Aktivität.
B. Wunsch, M. Zott, G. Höfner, *Arch. Pharm. (Weinheim)* **1993**, 326, 823- 830. DOI 0365-6233/93/1010-0823.

21. Tricyclic benzomorphan analogues by intramolecular Oxa-Pictet-Spengler reaction.
B. Wünsch, M. Zott, *Tetrahedron: Asymmetry* **1993**, 4, 2307 - 2310. DOI 0957-4166/93.
22. Homochirale 2,4-disubstituierte 1,3-Dioxane aus (S)-(-)-Äpfelsäure: Stereoselektive Synthese und Untersuchung der NMDA-Rezeptoraffinität aller vier Stereoisomere.
B. Wünsch, H. Diekmann, G. Höfner, *Liebigs Ann. Chem.* **1993**, 1273 - 1278. DOI 0170-2041/93/1212-1273.
23. CNS-agents: Optical resolution with baker's yeast as key step in the synthesis of optically active tricyclic amines.
B. Wünsch, H. Diekmann, *Heterocycles* **1994**, 38, 709 - 712.
24. Benzomorphan analogous CNS agents: Synthesis of homochiral epoxybenzocyclooctenamines.
B. Wünsch, M. Zott, G. Höfner, *Tetrahedron* **1994**, 50, 8003 - 8010. DOI 0040-4020/94.
25. A facile and regioselective synthesis of donor-substituted 2-(2-halophenyl)acetaldehyde acetals.
B. Wünsch, S. Nerdinger, *Arch. Pharm. (Weinheim)* **1995**, 328, 301 - 305. DOI 0365-6233/95/0404-0301.
26. Synthesis of donor-substituted 2-benzopyrans, isoquinolines, and cinnolines with acetal structure.
B. Wünsch, S. Nerdinger, G. Höfner, *Liebigs Ann.* **1995**, 1303 - 1312. DOI 0947-3440/95/0707-1203.
27. Tricyclic CNS active agents by intramolecular Oxa-Pictet-Spengler reaction.
B. Wünsch, M. Zott, G. Höfner, G. Bauschke, *Arch. Pharm. (Weinheim)* **1995**, 328, 487 - 495. DOI 0365-6233/95/0606-0487.
28. Stereoselective synthesis of 2-aminoethyl substituted tricycles with NMDA receptor affinity.
B. Wünsch, H. Diekmann, G. Höfner, *Tetrahedron: Asymmetry* **1995**, 6, 1527 - 1530. DOI 0957-4166/95.
29. Asymmetric synthesis of 1-Aryl-1,2,3,4-tetrahydroisoquinolines Part 1: Addition of chiral phenylacetaldehyde acetals to acylimines.
B. Wünsch, S. Nerdinger, *Tetrahedron Lett.* **1995**, 36, 8003 - 8006. DOI 0040-4039/95.

30. Synthesis of (1*S*,5*S*)-4,5-dihydro-1,5-epoxy-1*H*-2-benzoxocin-6(3*H*)-one from (*S*)-malic acid derivatives.
B. Wünsch, H. Diekmann, *Liebigs Ann.* **1996**, 69 - 76. DOI 0947-3440/96/0101-0069.
31. Benzomorphananalogue tricyclen: Synthese und pharmakologische Eigenschaften.
B. Wünsch, *Pharmazie in unserer Zeit* **1996**, 25, 260 - 266. DOI 0048-3664/96/05-0509-0260.
32. Stereoselective syntheses and CNS activity of novel tricyclic amines.
B. Wünsch, H. Diekmann, G. Höfner, *Pharmazie* **1997**, 52, 87 - 91.
33. Noncompetitive NMDA antagonists: A novel synthesis of 1-phenyltetrahydro-3-benzazepines.
B. Wünsch, S. Nerdinger, G. Bauschke, G. Höfner, *Arch. Pharm. Pharm. Med. Chem.* **1997**, 330, 211 - 214. DOI 0365-6233/97/0707-0211.
34. Asymmetric synthesis of 1-aryl-1,2,3,4-tetrahydroisoquinolines, 2: Preparation of chiral 2-(2-bromobenzyl)-1,3-dioxolanes and their addition to acylimines.
B. Wünsch, S. Nerdinger, *Eur. J. Org. Chem.* **1998**, 711 - 718. DOI 1434-193X/98/0404.
35. Investigation of the diastereoselectivity during the addition of an enantiomerically pure (2-Lithiophenyl)acetaldehyde acetal to various imines.
B. Wünsch, S. Nerdinger, *Chem. Lett.* **1998**, 799 - 800.
36. Diastereoselective addition of chiral (2-Lithiophenyl)acetaldehyde acetals to various imines as key step in the asymmetric synthesis of 1-aryltetrahydroisoquinolines, part 4.
B. Wünsch, S. Nerdinger, *Eur. J. Org. Chem.* **1999**, 503 - 517. DOI 1434-193X/99/0202-0503.
37. A facile synthesis of enantiomerically Pure 1-(Piperazin-2-yl)ethan-1-ol derivatives from (2*S*,3*R*)-Threonine.
S. Soukara, B. Wünsch, *Synthesis* **1999**, 10, 1739 - 1746. ISSN 0039-7881.
38. Stereoselective synthesis and receptor binding of conformationally restricted and flexible 2,4-disubstituted 1,3-dioxanes derived from benzomorphan.
B. Wünsch, G. Bauschke, H. Diekmann, G. Höfner, *Arch. Pharm. Pharm. Med. Chem.* **1999**, 332, 413 - 421. DOI 0365-6233/99/1212/0413.
39. Synthesis of 6,8-diazabicyclo[3.2.2]nonanes: Conformationally restricted piperazine derivatives.
M. Weigl, B. Wünsch, *Org. Lett.* **2000**, 2, 1177 - 1179. DOI 10.1021/ol990393a.

40. Wirkstoffgewinnung im Turbotempo.
B. Wünsch, *Pharm. Ztg.* **2000**, *145*, 3883 - 3888.
41. Synthesis of enantiomerically pure morphan analogues from α -D-glucose.
B. Streicher, B. Wünsch, *Eur. J. Org. Chem.* **2001**, 115 - 120. DOI 1434-193X/01/0101-0115.
42. Synthesis and stereoselective κ -receptor binding of methylated analogues of GR-89.696.
C. Röhr, S. Soukara, B. Wünsch, *Eur. J. Med. Chem.* **2001**, *36*, 211 - 214. PII: S0223-5234(00)01208-3/SCO.
43. Regioselective thionation of bicyclic piperazinediones.
S. Soukara, B. Wünsch, *Tetrahedron* **2001**, *57*, 4359 - 4363. PII: S0040-4020(01)00324-6.
44. (1-Benzylpiperazin-2-yl)methanols: novel EPC synthesis from (S)-serine and transformation into ligands for central nervous system receptors.
S. Bedürftig, M. Weigl, B. Wünsch, *Tetrahedron: Asymmetry* **2001**, *12*, 1293 - 1302. PII: S0957-4166(01)00208-7.
45. Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent κ -receptor agonists: Stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies.
S. Soukara, C. A. Maier, U. Predoiu, A. Ehret, R. Jackisch, B. Wünsch, *J. Med. Chem.* **2001**, *44*, 2814 - 2826. DOI 10.1021/jm0108395.
46. Synthesis and opioid-receptor binding of novel amino-substituted morphan analogues.
G. Höfner, B. Streicher, B. Wünsch, *Arch. Pharm. Pharm. Med. Chem.* **2001**, *334*, 284 - 290. DOI 0365-6233/01/0809/0284.
47. Novel spiro piperidines as highly potent and subtype selective σ -receptor ligands. part 1.
C. A. Maier, B. Wünsch, *J. Med. Chem.* **2002**, *45*, 438 - 448. DOI 10.1021/jm010992z.
48. Synthesis of chiral non-racemic 3-(dioxopiperazin-2-yl)propionic acid derivatives.
M. Weigl, B. Wünsch, *Tetrahedron* **2002**, *58*, 1173 - 1183. PII: S0040-4020(01)01212-1.
49. Conformationally constrained ethylenediamines: Synthesis and receptor binding of 6,8-diazabicyclo[3.2.2]nonanes.
M. Weigl, S. Bedürftig, C. A. Maier, B. Wünsch, *Bioorg. Med. Chem.* **2002**, *10*, 2245 - 2257. PII: S0968-0896(02)00043-3.

50. Novel σ receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] with carbon substituents in position 3.
C. A. Maier, B. Wünsch, *J. Med. Chem.* **2002**, *45*, 4923 - 4930. DOI 10.1021/jm020889p.
51. Synthesis and SAR studies of 3-substituted 1'-benzylspiro[[2]benzoxepine-1,4'-piperidines].
C. A. Maier, B. Wünsch, *Eur. J. Org. Chem.* **2003**, 714 - 720. DOI 1434-193X/03/0204.
52. Synthesis of amino-substituted hexo- and heptopyranoses from D-galactose.
B. Streicher, B. Wünsch, *Carbohydrate Res.* **2003**, *338*, 2375 - 2385. DOI 10.1016/S0008-6215(03)00382-3.
53. Welche Rolle spielt die Aminosäure Glutamat im Gehirn? Lernen, Gedächtnis und Zellzerstörung.
B. Wünsch, *Forschungsjournal Universität Münster*, Juni **2003**, 41 - 47.
54. Synthesis and NMDA-Receptor affinity of ring and side chain homologous dexoxadrol derivatives.
M. Aepkers, B. Wünsch, *Arch. Pharm. Pharm. Med. Chem.* **2004**, *337*, 67 - 75.
55. Synthesis and structure/NMDA receptor affinity relationships of 1-substituted tetrahydro-3-benzazepines.
O. Krull, B. Wünsch, *Bioorg. Med. Chem.* **2004**, *12*, 1439 - 1451. DOI 10.1016/j.bmc.2003.12.036.
56. Synthesis of regioisomeric azidobutanediols.
M. Aepkers, B. Wünsch, *Synthesis* **2004**, *7*, 1033-1036. DOI 10.1055/s-2004-822329.
57. Chiral, nonracemic (piperazin-2-yl)methanol derivatives with σ -receptor affinity.
S. Bedürftig, B. Wünsch, *Bioorg. Med. Chem.* **2004**, *12*, 3299 - 3311. DOI 10.1016/j.bmc.2004.03.059.
58. One pot solid phase synthesis of 2-substituted 2,3-dihydropyridin-4-(1H)-ones on Rinkamide-resin.
M. Sax, S. Berning, B. Wünsch, *Tetrahedron* **2005**, *61*, 205 - 211. DOI 10.1016/j.tet.2004.10.031.
59. Asymmetric synthesis of 1-substituted tetrahydro-3-benzoazepines.
U. Wirt, R. Fröhlich, B. Wünsch, *Tetrahedron: Asymmetry* **2005**, *16*, 2199 - 2202. DOI 10.1016/j.tetasy.2005.06.007.

60. Structure-affinity relationship studies of non-competitive NMDA receptor antagonists derived from dexoxadrol and etoxadrol.
M. Aepkers, B. Wünsch, *Bioorg. Med. Chem.* **2005**, *13*, 6836 - 6849. DOI 10.1016/j.bmc.2005.07.030.
61. Molecular modeling directed synthesis of bicyclic analogue of the δ opioid receptor agonist SNC 80.
B. Jung, W. Englberger, B. Wünsch, *Arch. Pharm. Chem. Life Sci.* **2005**, *338*, 281 - 290. DOI 10.1002/ardp.200400994.
62. Die bessere Hälfte bewährter Arzneistoffe.
B. Wünsch, *Pharm. Ztg.* **2005**, *30*, 16 - 23.
63. Stereoselectivity during a Dieckmann analogous cyclization of (piperazin-2-yl)propionic acid esters.
C. Geiger, C. Zelenka, R. Fröhlich, B. Wibbeling, B. Wünsch, *Z. Naturforsch.* **2005**, *60b*, 1068 - 1070. DOI 0932-0776/05/1000-1068.
64. Synthesis of N-acylated 7-amino-2,6,7-trideoxy-D-erythroheptopyranosides from methyl α -D-mannoside.
K. Wiedemeyer, B. Wünsch, *Carbohydrate Res.* **2005**, *340*, 2483 - 2493. DOI 10.1016/j.carres.2005.08.008.
65. Synthesis and receptor binding studies of 3-substituted piperazine derivatives.
S. Bedürftig, B. Wünsch, *Eur. J. Med. Chem.* **2006**, *41*, 387 - 396. DOI 10.1016/j.ejmech.2005.09.004.
66. Relationships between the structure of dexoxadrol and etoxadrol analogues and their NMDA receptor affinity.
M. Sax, B. Wünsch, *Current Topics in Med. Chem.* **2006**, *6*, 723 - 732. DOI 1568-0266/06.
67. Synthesis and NMDA-receptor affinity of 4-oxo-dexoxadrol derivatives.
M. Sax, K. Ebert, D. Schepmann, B. Wibbeling, B. Wünsch, *Bioorg. Med. Chem.* **2006**, *14*, 5955 - 5962. DOI 10.1016/j.bmc.2006.05.020.
68. Synthesis of novel σ -receptor ligands from methyl α -D-mannopyranoside.
K. Wiedemeyer, B. Wünsch, *Carbohydr. Res.* **2006**, *341*, 2321 - 2334. DOI 10.1016/j.carres.2006.06.016.
69. Synthesis and pharmacological characterization of sila-panamesine, a sila-analogue of the σ receptor ligand panamesine (EMD 57445).
R. Ilg, C. Burschka, D. Schepmann, B. Wünsch, R. Tacke, *Organometallics* **2006**, *25*, 5396 - 5408. DOI 10.1021/om060562c.

70. Computer simulation of asymmetric transformations.
J. Köhler, B. Wünsch, *Tetrahedron: Asymmetry* **2006**, *17*, 3100 - 3110. DOI 10.1016/j.tetasy.2006.11.040.
71. Lipase catalyzed enantioselective desymmetrization of a prochiral pentane-1,3,5-triol derivative.
J. Köhler, B. Wünsch, *Tetrahedron: Asymmetry* **2006**, *17*, 3091 - 3099. DOI 10.1016/j.tetasy.2006.10.043.
72. Chemoenzymatic synthesis of enantiomerically pure tricyclic benzomorphan analogues.
C. Ketterer, S. Grimme, E. Weckert, B. Wünsch, *Tetrahedron: Asymmetry* **2006**, *17*, 3046 - 3050. DOI 10.1016/j.tetasy.2006.11.020.
73. Asymmetric synthesis of 1-substituted tetrahydro-3-benzazepines as NMDA receptor antagonists.
U. Wirt, D. Schepmann, B. Wünsch, *Eur. J. Org. Chem.* **2007**, 462 - 475. DOI 10.1002/ejoc.200600746.
74. Synthesis of bridged piperazines with σ receptor affinity.
M. Weigl, B. Wünsch, *Eur. J. Med. Chem.* **2007**, *42*, 1247 - 1262. DOI 10.1016/j.ejmech.2007.02.005.
75. The allosteric modulation of lipases and its possible biological relevance.
J. Köhler, B. Wünsch, *Theor. Biol. Med. Mod.* **2007**, 4:34 (16 pages). DOI 10.1186/1742-4682-4-34.
76. Synthesis of bicyclic σ receptor ligands with cytotoxic activity.
C. Geiger, C. Zelenka, M. Weigl, R. Fröhlich, B. Wibbeling, K. Lehmkuhl, D. Schepmann, R. Grünert, P. J. Bednarski, B. Wünsch, *J. Med. Chem.* **2007**, *50*, 6144 - 6153. DOI 10.1021/jm070620b.
77. Sila-haloperidol, a silicon analogue of the dopamine (D₂) receptor antagonist haloperidol: Synthesis, pharmacological properties, and metabolic fate.
R. Tacke, F. Popp, B. Müller, B. Theis, C. Burschka, A. Hamacher, M. U. Kassack, D. Schepmann, B. Wünsch, U. Jurva, E. Wellner, *ChemMedChem* **2008**, *3*, 152 - 164.
78. Synthesis and structure-affinity relationships of novel spirocyclic σ receptor ligands with furopyrazole structure.
T. Schläger, D. Schepmann, E.-U. Würthwein, B. Wünsch, *Bioorg. Med. Chem.* **2008**, *16*, 2992 - 3001. DOI 10.1016/j.bmc.2007.12.045.
79. Synthesis and pharmacological evaluation of bicyclic SNC80 analogues with separated benzhydryl moiety.
B. Jung, W. Englberger, R. Fröhlich, D. Schepmann, K. Lehmkuhl, B. Wünsch, *Bioorg. Med. Chem.* **2008**, *16*, 2870 - 2885. DOI 10.1016/j.bmc.2008.01.004.

80. Quality and functionality of saffron: Quality control, species assortment and affinity of extract and isolated saffron compounds to NMDA and σ_1 (Sigma-1) receptors. M. Lechtenberg, D. Schepmann, M. Niehues, N. Hellenbrand, B. Wünsch, A. Hensel, *Planta Medica* **2008**, *74*, 764 - 772. DOI 10.1055/s-2008-1074535.
81. A new, efficient and direct preparation of TITp and related complexes with TIBH₄. M. Kitamura, Y. Takenaka, T. Okuno, R. Holl, B. Wünsch, *Eur. J. Inorg. Chem.* **2008**, 1188 - 1192. DOI 10.1002/ejic.200701366.
82. Novel, one-pot procedure for the synthesis of 2-arylethanol derivatives. T. Schläger, C. Oberdorf, B. Tewes, B. Wünsch, *Synthesis* **2008**, 1793 - 1797. DOI 10.1055/s-2008-1067021.
83. Synthesis of 2,5-Diazabicyclo[2.2.2]octanes by Dieckmann analogous cyclization. R. Holl, M. Dykstra, M. Schneiders, R. Fröhlich, M. Kitamura, E.-U. Würthwein, B. Wünsch, *Austr. J. Chem.* **2008**, *61*, 914 - 919. DOI 10.1071/CH08350.
84. Synthesis of phenylacetic acids with 2-Oxoalkyl substituents in *ortho*-position from *o*-phenylenediacetic acid. S. M. Husain, B. Wünsch, *Synthesis* **2008**, 2729 - 2732. DOI 10.1055/s-2008-1067201.
85. A very short asymmetric synthesis of enantiomerically pure methyl substituted tetrahydro-3-benzazepines. S. M. Husain, R. Fröhlich, B. Wünsch, *Tetrahedron: Asymmetry* **2008**, *19*, 1613 - 1616. DOI 10.1016/j.tetasy.2008.06.016.
86. Thiophene bioisosteres of spirocyclic σ receptor ligands. 1. N-substituted spiro[piperidine-4,4'-thieno[3,2-c]pyrans]. C. Oberdorf, D. Schepmann, J. M. Vela, J. L. Diaz, J. Holenz, B. Wünsch, *J. Med. Chem.* **2008**, *51*, 6531 - 6537. DOI 10.1021/jm8007739.
87. Synthesis and NMDA receptor affinity of ring and side chain homologues of dexoxadrol. M. Sax, R. Fröhlich, D. Schepmann, B. Wünsch, *Eur. J. Org. Chem.* **2008**, 6015 - 6028. DOI 10.1002/ejoc.200800727.
88. 1,4-diazepanes derived from (S)-serine – homopiperazines with improved σ_1 (sigma) receptor affinity and selectivity. S. Bedürftig, B. Wünsch, *Eur. J. Med. Chem.* **2009**, *44*, 519 - 525. DOI 10.1016/j.ejmech.2008.03.033.
89. Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their σ receptor affinity and cytotoxic activity. R. Holl, D. Schepmann, R. Grünert, P. J. Bednarski, B. Wünsch, *Bioorg. Med. Chem.* **2009**, *17*, 777 - 793. DOI 10.1016/j.bmc.2008.11.043.

90. Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their σ receptor affinity and cytotoxic activity.
R. Holl, D. Schepmann, P.J. Bednarski, R. Grünert, B. Wünsch, *Bioorg. Med. Chem.* **2009**, *17*, 1445 - 1455. DOI 10.1016/j.bmc.2009.01.012.
91. Accurate quantification of DNA methylation of DRD4 applying capillary gel electrophoresis with LIF detection.
S. Goedecke, S. Schlosser, J. Mühlisch, G. Hempel, M. C. Frühwald, B. Wünsch, *Electrophoresis* **2009**, *30*, 1412 - 1417. DOI 10.1002/elps.200800567.
92. Structure-affinity-relationship study of bicyclic σ receptor ligands.
R. Holl, C. Geiger, M. Nambo, K. Itami, D. Schepmann, B. Wünsch, *Central Nervous System Agents in Medicinal Chemistry, Special Issue* **2009**, *9*, 220 - 229. DOI 1871-5249/09.
93. Pharmacological and metabolic characterisation of the potent σ_1 receptor ligand 1'-benzyl-3-methoxy-3H-spiro[[2]benzofuran-1,4'-piperidine].
C. Wiese, E. Große Maestrup, D. Schepmann, J. M. Vela, J. Holenz, H. Buschmann, B. Wünsch, *J. Pharm. Pharmacol.* **2009**, *61*, 631 - 640. DOI 10-1211/jpp/61.05.0012.
94. Dancing of the second aromatic residue around the 6,8-Diazabicyclo[3.2.2]-nonane framework: Influence on σ receptor affinity and cytotoxicity.
R. Holl, D. Schepmann, R. Fröhlich, R. Grünert, P. J. Bednarski, B. Wünsch, *J. Med. Chem.* **2009**, *52*, 2126 - 2137. DOI 10.1021/jm801522j.
95. Synthesis of spirocyclic σ_1 receptor ligands as potential PET radiotracers, structure-affinity relationships and in vitro metabolic stability.
E. Große Maestrup, C. Wiese, D. Schepmann, A. Hiller, S. Fischer, M. Scheunemann, P. Brust, B. Wünsch, *Bioorg. Med. Chem.* **2009**, *17*, 3630 - 3641. DOI 10.1016/j.bmc.2009.03.060.
96. Synthesis of 1,4-Diazabicyclo[3.3.1]nonan-6-ones.
D. Kracht, S. Saito, B. Wünsch, *Austr. J. Chem.* **2009**, *62*, 1684 - 1689. DOI 10.1071/CH09206.
97. Asymmetric synthesis of enantiomerically pure 2-substituted tetrahydro-3-benzazepines and their affinity to σ_1 receptors.
S. M. Husain, R. Fröhlich, D. Schepmann, B. Wünsch, *J. Org. Chem.* **2009**, *74*, 2788 - 2793. DOI 10.1021/jo900087e.
98. Synthesis of σ receptor ligands with unsymmetrical spiro connection of the piperidine moiety.
A. Jasper, D. Schepmann, K. Lehmkuhl, J. M. Vela, H. Buschmann, J. Holenz, B. Wünsch, *Eur. J. Med. Chem.* **2009**, *44*, 4306 - 4314. DOI 10.1016/j.ejmech.2009.07.017.

99. Asymmetric synthesis and σ receptor affinity of enantionerically pure 1,4-disubstituted tetrahydro-1*H*-3-benzazepines.
S. M. Husain, M. T. Heim, D. Schepmann, B. Wünsch, *Tetrahedron: Asymmetry* **2009**, 20, 1383 - 1392. DOI 10.1016/j.tetasy.2009.05.017.
100. Synthesis and pharmacological evaluation of SNC80 analogues with a bridged piperazine ring.
R. Holl, B. Jung, D. Schepmann, H.-U. Humpf, R. Grünert, P. J. Bednarski, W. Englberger, B. Wünsch, *ChemMedChem* **2009**, 4, 2111 - 2122. DOI 10.1002/cmdc.200900358.
101. Determination of DNA methylation by COBRA: A comparative study of CGE with LIF detection and conventional gel electrophoresis.
S. Goedecke, S. Schlosser, J. Mühlisch, G. Hempel, M. C. Frühwald, B. Wünsch, *Electrophoresis* **2009**, 30, 3063 - 3070. DOI 10.1002/elps.200900204.
102. Fe-catalyzed oxidative coupling of heteroarenes and methylamines.
M. Ohta, M. P. Quick, J. Yamaguchi, B. Wünsch, K. Itami, *Chem. Asian J.* **2009**, 4, 1416 - 1419. DOI 10.1002/asia.200900157.
103. Evaluation of spirocyclic 3-(3-fluoropropyl)-2-benzofurans as σ_1 receptor ligands for neuroimaging with positron emission tomography.
E. Große Maestrup, S. Fischer, C. Wiese, D. Schepmann, A. Hiller, W. Deuther-Conrad, J. Steinbach, B. Wünsch, P. Brust, *J. Med. Chem.* **2009**, 52, 6062 - 6072. DOI 10.1021/jm900909e.
104. Synthesis of a silanol-substituted proline Analog as organocatalyst.
D. Kracht, S. Saito, R. Fröhlich, B. Wünsch, *Z. Naturforsch.*, **2009**, 64b, 1169 - 1175. DOI 0932-0776/09/1000-1169.
105. Stereoselective synthesis and structure-affinity relationships of bicyclic κ receptor agonists.
D. Kracht, E. Rack, D. Schepmann, R. Fröhlich, B. Wünsch, *Org. Biomol. Chem.* **2010**, 8, 212 - 225. DOI 10.1039/b915180j.
106. Enantioselective synthesis of a 2,2-disubstituted tetrahydro-3-benzazepines as novel NMDA receptor antagonist.
S. M. Husain, R. Fröhlich, D. Schepmann, B. Wünsch, *Z. Naturforsch.* **2010**, 65b, 191 - 196. DOI 0932-0776/10/0200-0191.
107. Aromatic C-H bond hydroxylation by P450 peroxygenases: a facile colorimetric assay for monooxygenation activities of enzymes based on the Russig's blue formation.
O. Shoji, C. Wiese, T. Fujishiro, C. Shirataki, B. Wünsch, Y. Watanabe, *J. Biol. Inorg. Chem.* **2010**, 15, 1109 - 1115. DOI 10.1007/s00775-010-0671-9.

108. Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors.
D. Schepmann, B. Frehland, K. Lehmkuhl, B. Tewes, B. Wünsch, *J. Pharm. Biomed. Anal.* **2010**, *53*, 603 - 608. DOI 10.1016/j.jpba.2010.04.014.
109. Synthesis of Iminodiacetaldehyde derivatives as building blocks for the pharmacologically active agents.
Y. Fricke, N. Kopp, B. Wünsch, *Synthesis* **2010**, 791 - 796. DOI 10.1055/s-0029-1218622.
110. Design, synthesis, and biological evaluation of 3-benzazepin-1-ols as NR2B-selective NMDA receptor antagonists.
B. Tewes, B. Frehland, D. Schepmann, K.-U. Schmidtke, T. Winckler, B. Wünsch, *ChemMedChem* **2010**, *5*, 687 - 695. DOI 10.1002/cmdc.201000005.
111. Synthesis and NMDA receptor affinity of dexoxadrol analogues with modifications in position 4 of the piperidine ring.
A. Banerjee, R. Fröhlich, D. Schepmann, B. Wünsch, *MedChemComm* **2010**, *1*, 87 - 102. DOI 10.1039/c0md00017e.
112. Bivalent β -carbolines as potential multitarget anti-Alzheimer agents.
Y. Rook, K.-U. Schmidtke, F. Gaube, D. Schepmann, B. Wünsch, J. Heilmann, J. Lehmann, T. Winckler, *J. Med. Chem.* **2010**, *53*, 3611 - 3617. DOI 10.1021/jm1000024.
113. Design, synthesis and SAR analysis of novel selective σ_1 ligands (Part 2).
D. Rossi, M. Urbano, A. Pedrali, M. Serra, D. Zampieri, M. G. Mamolo, C. Laggner, C. Zanette, C. Florio, D. Schepmann, B. Wünsch, O. Azzolina, S. Collina, *Bioorg. Med. Chem.* **2010**, *18*, 1204 - 1212. DOI 10.1016/j.bmc.2009.12.039.
114. 5D-QSAR for spirocyclic σ_1 receptor ligands by Quasar receptor surface modeling.
C. Oberdorf, T. J. Schmidt, B. Wünsch, *Eur. J. Med. Chem.* **2010**, *45*, 3116 - 3124. DOI 10.1016/j.ejmech.2010.03.048.
115. (3R,11aR)-3-Phenyl-2,3,11,11a-tetrahydro-[1,3]oxazolo[3,2-b]-[2]-benzazepin-5(10H)-one as chiral building block for the asymmetric synthesis of 3-substituted 2-benzazepines.
M. P. Quick, R. Fröhlich, B. Wünsch, *Tetrahedron: Asymmetry* **2010**, *21*, 524 - 526. DOI 10.1016/j.tetasy.2010.03.019.
116. Conformationally constrained κ receptor agonists: Stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.
C. Geiger, C. Zelenka, K. Lehmkuhl, D. Schepmann, W. Englberger, B. Wünsch, *J. Med. Chem.* **2010**, *53*, 4212 - 4222. DOI 10.1021/jm100182p.

117. Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues.
A. Banerjee, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2010**, *18*, 4095 - 4102. DOI 10.1016/j.bmc.2010.04.002.
118. Bicyclic σ receptor ligands by stereoselective Dieckmann analogous cyclization of piperazinebutyrate.
S. K. Sunnam, D. Schepmann, B. Wibbeling, B. Wünsch, *Org. Biomol. Chem.* **2010**, *8*, 3715 - 3722. DOI 10.1039/c003878d.
119. Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
B. Tewes, B. Frehland, D. Schepmann, K.-U. Schmidtke, T. Winckler, B. Wünsch, *Bioorg. Med. Chem.* **2010**, *18*, 8005 - 8015. DOI 10.1016/j.bmc.2010.09.026.
120. Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists.
A. Banerjee, D. Schepmann, J. Köhler, E.-U. Würthwein, B. Wünsch, *Bioorg. Med. Chem.* **2010**, *18*, 7855 - 7867. DOI 10.1016/j.bmc.2010.09.047.
121. Synthesis and biological evaluation of conformationally restricted σ_1 receptor ligands with 7,9-diazabicyclo[4.2.2]decane scaffold.
S. K. Sunnam, D. Schepmann, E. Rack, R. Fröhlich, K. Korpis, P. J. Bednarski, B. Wünsch, *Org. Biomol. Chem.* **2010**, *8*, 5525 - 5540. DOI 10.1039/c0ob00402b.
122. Synthesis and biological evaluation of a radioiodinated spiro piperidine ligand as a potential σ_1 receptor imaging agent.
R.-Q. Chen, Y. Li, Q.-Y. Zhang, H.-M. Jia, W. Deuther-Conrad, D. Schepmann, J. Steinbach, P. Brust, B. Wünsch, B.-L. Liu, *J. Label. Compd. Radiopharm.* **2010**, *53*, 569 - 574. DOI 10.1002/jlcr.1777.
123. Frontiers in medicinal chemistry 2010: The highlights
D. Schepmann, B. Wünsch, *ChemMedChem* **2010**, *5*, 949 - 954. DOI 10.1002/cmdc.201000193.
124. Synthesis, pharmacological activity and structure affinity relationships of spirocyclic σ_1 receptor ligands with a (2-fluoroethyl) residue in 3-position.
E. Große Maestrup, C. Wiese, D. Schepmann, P. Brust, B. Wünsch, *Bioorg. Med. Chem.* **2011**, *19*, 393 - 405. DOI 10.1016/j.bmc.2010.11.013.
125. Enantioselective σ_1 receptor binding and biotransformation of the spirocyclic PET tracer 1-benzyl-3-(3-fluoropropyl)-3*H*-spiro[[2]benzofuran-1,4'-piperidine].
C. Wiese, E. Große Maestrup, D. Schepmann, S. Grimme, H.-U. Humpf, P. Brust, B. Wünsch, *Chirality* **2011**, *23*, 148 - 154. DOI 10.1002/chir.20893.

126. Expression of σ receptors of human urinary bladder tumor cells (RT-4 cells) and development of a competitive receptor binding assay for the determination of ligand affinity to human σ_2 receptors.
D. Schepmann, K. Lehmkuhl, S. Brune, B. Wünsch, *J. Pharm. Biomed. Anal.* **2011**, *55*, 1136 - 1141. DOI 10.1016/j.jpba.2011.03.044.
127. Molecular imaging of σ receptors: synthesis and evaluation of the potent σ_1 selective radioligand [^{18}F]fluspidine.
S. Fischer, C. Wiese, E. Große Maestrup, A. Hiller, W. Deuther-Conrad, M. Scheunemann, D. Schepmann, J. Steinbach, B. Wünsch, P. Brust, *Eur. J. Nucl. Med. Mol. Imaging* **2011**, *38*, 540 - 551. DOI 10.1007/s00259-010-1658-z.
128. Synthesis of 7,9-diazabicyclo[4.2.2]decanes as conformationally restricted κ receptor agonists: Fine tuning of the dihedral angle of the ethylenediamine pharmacophore.
S. K. Sunnam, E. Rack, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2011**, *46*, 1972 - 1982. DOI 10.1016/j.ejmech.2011.01.064.
129. Synthesis and pharmacological evaluation of a potent and selective σ_1 receptor antagonist with high antiallodynic activity.
T. Utech, J. Köhler, H. Buschmann, J. Holenz, J. M. Vela, B. Wünsch, *Arch. Pharm. Chem. Life Sci.* **2011**, *344*, 415 - 421. DOI 10.1002/ardp.201000365.
130. Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonists.
T. Utech, J. Köhler, B. Wünsch, *Eur. J. Med. Chem.* **2011**, *46*, 2157 - 2169. DOI 10.1016/j.ejmech.2011.02.070.
131. Design, synthesis and pharmacological evaluation of spirocyclic σ_1 receptor ligands with exocyclic amino moiety (increased distance 1).
E. Rack, R. Fröhlich, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2011**, *19*, 3141 - 3151. DOI 10.1016/j.bmc.2011.04.002.
132. Synthesis and in vitro evaluation of novel indole-based sigma receptors ligands.
M. Yarim, M. Koksal, D. Schepmann, B. Wünsch, *Chem. Bio. Drug Design* **2011**, *78*, 869 - 875. DOI 10.1111/j.1747-0285.2011.01215.x.
133. Arzneistoffe mit maßgeschneiderten Eigenschaften.
J. Fabian, D. Schepmann, B. Wünsch, *Pharm. Ztg.* **2011**, *156*, 15 - 21.
134. Encecalol angelate, an unstable chromene from *Ageratum conyzoides* L.: Total synthesis and investigation of its antiprotozoal activity.
D. Harel, S. A. Khalid, M. Kaiser, R. Brun, B. Wünsch, T. J. Schmidt, *J. Ethnopharmacol.* **2011**, *137*, 620 - 625. DOI 10.1016/j.jep.2011.06.015.

135. A ^{18}F -Labeled fluorobutyl-substituted spirocyclic piperidine derivative as a selective radioligand for PET imaging of σ_1 receptors.
A. Maisonia, E. Große Mastrup, S. Fischer, A. Hiller, M. Scheunemann, C. Wiese, D. Schepmann, J. Steinbach, W. Deuther-Conrad, B. Wünsch, P. Brust, *ChemMedChem* **2011**, 6, 1401 - 1410. DOI 10.1002/cmdc.201100108.
136. Asymmetric synthesis of enantiomerically pure 1,4-di- and 1,1,4-trisubstituted tetrahydro-1*H*-3-benzazepines.
S. Sarkar, D. Schepmann, B. Wünsch, *Tetrahedron: Asymmetry* **2011**, 22, 1411 - 1422. DOI 10.1016/j.tetasy.2011.07.027.
137. Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ_1 receptor affinity.
T. Schläger, D. Schepmann, K. Lehmkuhl, J. Holenz, J. M. Vela, H. Buschmann, B. Wünsch, *J. Med. Chem.* **2011**, 54, 6704 - 6713. DOI 10.1021/jm200585k.
138. Exploitation of an additional hydrophobic pocket of σ_1 receptors: Late-stage diverse modifications of spirocyclic thiophenes by C-H bond functionalization.
C. Meyer, B. Neue, D. Schepmann, S. Yanagisawa, J. Yamaguchi, E.-U. Würthwein, K. Itami, B. Wünsch, *Org. Biomol. Chem.* **2011**, 9, 8016 - 8029. DOI 10.1039/c1ob06149f.
139. Novel σ_1 receptor ligands by oxa-pictet-spengler reaction of pyrazolyethanol.
T. Schläger, D. Schepmann, B. Wünsch, *Synthesis* **2011**, 3965 - 3974. DOI 10.1055/s-0031-1289607.
140. Identification of a potent and selective sigma1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells.
S. Collina, D. Rossi, A. Pedrali, M. Urbano, R. Gaggeri, M. Serra, L. Fernández, M. Fernández, J. Caballero, S. Ronsisvalle, O. Prezzavento, M. Peviani, D. Curti, O. Azzolina, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2011**, 19, 6210 - 6224. DOI 10.1016/j.bmc.2011.09.016.
141. High-affinity, selective σ ligands of the 1,2,3,4-tetrahydro-1,4'-silaspiro[naphthalene-1,4'-piperidine] type: Synthesis, structures, and pharmacological properties.
R. Tacke, R. Bertermann, C. Burschka, S. Dörrich, M. Fischer, B. Müller, G. Meyerhans, D. Schepmann, B. Wünsch, I. Arnason, R. Björnsson, *ChemMedChem* **2012**, 7, 523 - 532. DOI 10.1002/cmdc.201100423.
142. Pharmacophore models and development of spirocyclic ligands for σ_1 receptor.
B. Wünsch, *Curr. Pharm. Design* **2012**, 18, 930 - 937. DOI 10.1080/10817331.2012.704122.

143. Synthesis, radiofluorination and pharmacological evaluation of a fluoromethyl spirocyclic PET tracer for central σ_1 receptors and comparison with fluoroalkyl homologs.
A. Maisonal, E. Große Maestrup, C. Wiese, A. Hiller, D. Schepmann, S. Fischer, W. Deuther-Conrad, J. Steinbach, P. Brust, B. Wünsch, *Bioorg. Med. Chem.* **2012**, *20*, 257 - 269. DOI 10.1016/j.bmc.2011.11.002.
144. Genome-wide DNA methylation level analysis by MEKC-LIF after treatment of cell lines with azacytidine and antifolates.
E. Falck, A. Groenhagen, J. Mühlisch, G. Hempel, B. Wünsch, *Anal. Biochem.* **2012**, *421*, 439 - 445. DOI 10.1016/j.ab.2011.09.027.
145. Characterization of ligand binding to the σ_1 receptor in a human tumor cell line (RPMI 8226) and establishment of a competitive receptor binding assay.
S. Brune, D. Schepmann, B. Frehland, K. Lehmkuhl, B. Wünsch, *Assay Drug Dev. Technol.* **2012**, *10*, 365 - 374. DOI 10.1089/adt.2011.0376.
146. Microwave assisted synthesis of 3-benzazepin-2-ones as building blocks for 2,3-disubstituted tetrahydro-3-benzazepines.
S. Sarkar, S. M. Husain, D. Schepmann, R. Fröhlich, B. Wünsch, *Tetrahedron* **2012**, *68*, 2687 - 2695. DOI 10.1016/j.tet.2012.01.052.
147. Conversion of a pentane-1,3,5-triol derivative using lipases as chiral catalysts and possible function of the lid for the regulation of substrate selectivity and enantioselectivity.
J. Köhler, B. Wünsch, *Biocatalysis & Biotransformation* **2012**, *30*, 217 - 225. DOI 10.3109/10242422.2012.661726.
148. Lipase catalyzed kinetic resolution of 2-phenylethanol derivatives and chiral oxapictet-spengler reaction as the key steps in the synthesis of enantiomerically pure tricyclic amines.
C. Ketterer, B. Wünsch, *Eur. J. Org. Chem.* **2012**, 2428 - 2444. DOI 10.1002/ejoc.201101800.
149. Microwave assisted synthesis of spirocyclic pyrrolidines – σ_1 receptor ligands with modified benzene-*N*-distance.
A. Jasper, D. Schepmann, K. Lehmkuhl, J. M. Vela, H. Buschmann, J. Holenz, B. Wünsch, *Eur. J. Med. Chem.* **2012**, *53*, 327 - 336. DOI 10.1016/j.ejmech.2012.04.018.
150. Asymmetric synthesis of potent and selective σ_1 receptor ligands with tetrahydro-3-benzazepine scaffold.
S. Sarkar, D. Schepmann, J. Köhler, R. Fröhlich, B. Wünsch, *Eur. J. Org. Chem.* **2012**, 5980 - 5990. DOI 10.1002/ejoc.201200927.

151. Late-stage C-H bond arylation of spirocyclic σ_1 ligands for analysis of complementary σ_1 receptor surface.
C. Meyer, D. Schepmann, S. Yanagisawa, J. Yamaguchi, K. Itami, B. Wünsch, *Eur. J. Org. Chem.* **2012**, 5972 - 5979. DOI 10.1002/ejoc.201200837.
152. Thiophene bioisosteres of spirocyclic σ receptor ligands: Relationships between substitution pattern and σ receptor affinity.
C. Oberdorf, D. Schepmann, J. M. Vela, H. Buschmann, J. Holenz, B. Wünsch, *J. Med. Chem.* **2012**, 55, 5350 - 5360. DOI 10.1021/jm300302p.
153. Homologous piperazine-alcanols: chiral pool synthesis and pharmacological evaluation.
R. Holl, D. Schepmann, B. Wünsch, *MedChemComm* **2012**, 3, 673 - 679. DOI 10.1039/c2md20070h.
154. From mannose to morphan analogues: methyl α -D-mannoside as chiral building block for the synthesis of mono- and bicyclic σ receptor ligands.
K. Wiedemeyer, B. Wünsch, *Carbohydrate Res.* **2012**, 359, 24 - 29. DOI 10.1016/j.carres.2012.05.006.
155. Mit Elektrophorese einen Blick auf die DNA werfen.
E. Falck, B. Wünsch, *Laborwelt* **2012**, 2, 27 - 28.
156. Pd-catalyzed direct C-H bond functionalization of spirocyclic σ_1 ligands: Generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ_1 receptor.
C. Meyer, D. Schepmann, S. Yanagisawa, J. Yamaguchi, V. Dal Col, E. Laurini, K. Itami, S. Pricl, B. Wünsch, *J. Med. Chem.* **2012**, 55, 8047 - 8065. DOI 10.1021/jm300894h.
157. Enantiomerically pure 1,3-dioxanes as highly selective NMDA and σ_1 receptor ligands.
J. Köhler, K. Bergander, J. Fabian, D. Schepmann, B. Wünsch, *J. Med. Chem.* **2012**, 55, 8953 - 8957. DOI 10.1021/jm301166m.
158. The σ_1 receptor antagonist S1RA Is a promising candidate for the treatment of neurogenic pain.
B. Wünsch, Viewpoint article *J. Med. Chem.* **2012**, 55, 8209 - 8210. DOI 10.1021/jm3011993.
159. Solid-phase organic synthesis of dexoxadrol analogues.
M. Sax, B. Wünsch, *Austr. J. Chem.* **2013**, 66, 93 - 97. DOI 10.1071/CH12356.

160. Improvement of σ_1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones.
C. Meyer, B. Neue, D. Schepmann, S. Yanagisawa, J. Yamaguchi, E.-U. Würthwein, K. Itami, B. Wünsch, *Bioorg. Med. Chem.* **2013**, *21*, 1844 - 1856. DOI 10.1016/j.bmc.2013.01.038.
161. Unexpected formation of thiophene-annulated tetrahydro-3-benzazepines by alkylation of thiolactams with ethyl bromoacetate.
S. Sarkar, R. Fröhlich, B. Wünsch, *Z. Naturforsch.* **2013**, *68b*, 223 - 228. DOI 10.5560/ZNB.2013-3030.
162. Analysis of the molecular interactions of the potent analgesic S1RA with the σ_1 receptor.
E. Laurini, V. Dal Col, S. Pricl, B. Wünsch, *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2868 - 2871. DOI 10.1016/j.bmcl.2013.03.087.
163. Heck reaction of ortho-substituted iodobenzenes with α,β -unsaturated nitriles as key step in the synthesis of tetrahydro-2-benzazepines and hexahydro-3-benzazocines.
P. Hasebein, K. Aulinger, D. Schepmann, B. Wünsch, *Tetrahedron* **2013**, *69*, 4552 - 4562. DOI 10.1016/j.tet.2013.04.017.
164. Synthesis of thiophene-based TAK-779 analogues by C-H arylation.
A. Junker, J. Yamaguchi, K. Itami, B. Wünsch, *J. Org. Chem.* **2013**, *78*, 5579 - 5586. DOI 10.1021/jo400692p.
165. Chemical, pharmacological and in vitro metabolic stability studies on enantiomerically pure RC-33 compounds, promising neuroprotective agents acting as σ_1 receptor agonists.
D. Rossi, A. Pedrali, R. Gaggeri, A. Marra, L. Pignataro, E. Laurini, V. Dal Col, M. Fermeglia, S. Pricl, D. Schepmann, B. Wünsch, M. Peviani, D. Curti, S. Collina, *ChemMedChem* **2013**, *8*, 1514 - 1527. DOI 10.1002/cmdc.201300218.
166. Studies on the enantiomers of RC-33 as neuroprotective agents. Isolation, configurational assignment, and preliminary biological profile.
D. Rossi, A. Pedrali, R. Gaggeri, L. Pignataro, D. Schepmann, L. Ye, K. Leuner, O. Azzolina, B. Wünsch, S. Collina, *Chirality*, **2013**, *25*, 814 - 822. DOI 10.1002/chir.22223.
167. New combination of pharmacophoric elements of potent σ_1 ligands: Design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes.
D. Harel, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2013**, *69*, 490 - 497. DOI 10.1016/j.ejmech.2013.09.006.

168. Natural product derived antiprotozoal agents: Synthesis, biological evaluation and structure-activity relationships of novel chromene and chromane derivatives. D. Harel, D. Schepmann, H. Prinz, R. Brun, T. J. Schmidt, B. Wünsch, *J. Med. Chem.* **2013**, *56*, 7442 - 7448. DOI 10.1021/jm401007p.
169. Design, synthesis and receptor affinity of novel conformationally restricted σ ligands based on the [4.3.3]propellane scaffold. H. Torres-Gómez, K. Lehmkuhl, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2013**, *70*, 78 - 87. DOI 10.1016/j.ejmech.2013.09.021.
170. Synthesis, characterization, and metabolism studies of fluspidine enantiomers. K. Holl, E. Falck, J. Köhler, D. Schepmann, H.-U. Humpf, P. Brust, B. Wünsch, *ChemMedChem* **2013**, *8*, 2047 - 2056. DOI 10.1002/cmdc.201300322.
171. Enantioselective synthesis of enecaline-derived potent antimalarial agents. D. Harel, D. Schepmann, R. Brun, T. J. Schmidt, B. Wünsch. *Org. Biomol. Chem.* **2013**, *11*, 7342 - 7349. DOI 10.1039/c3ob41583j.
172. Radiofluorination and biological evaluation of *N*-aryl-oxadiazolyl-propionamides as potential radioligands for PET imaging of cannabinoid CB₂ receptors. R. Teodoro, R.-P. Moldovan, C. Lueg, R. Günther, C. K. Donat, F.-A. Ludwig, S. Fischer, W. Deuther-Conrad, B. Wünsch, P. Brust, *Org. Med. Chem. Lett.* **2013**, *1*, 11. DOI 10.1186/2191-2858-3-11.
173. Development of fluorinated CB₂ receptor agonists for PET studies. C. Lueg, D. Schepmann, R. Günther, P. Brust, B. Wünsch, *Bioorg. Med. Chem.* **2013**, *21*, 7481 - 7498. DOI 10.1016/j.mbc.2013.09.040.
174. Spiro[[1]benzothiophen-4,4'-piperidines] – carba analogs of potent σ_1 ligands. D. Harel, D. Schepmann, B. Wünsch, *MedChemComm* **2013**, *4*, 1604 - 1612. DOI 10.1039/c3md00228d.
175. Structure of the σ_1 receptor and its ligand binding site. S. Brune, S. Pricl, B. Wünsch, *J. Med. Chem.* **2013**, *56*, 9809 - 9819. DOI 10.1021/jm400660u.
176. Hydroxyalkylation with cyclic sulfates: Synthesis of carbazole derived CB₂ ligands with increased polarity. C. Lueg, F. Galla, B. Frehland, D. Schepmann, C. G. Daniliuc, W. Deuther-Conrad, P. Brust, B. Wünsch, *Arch. Pharm. Chem. Life Sci.* **2014**, *347*, 21 - 31. DOI 10.1002/ardp.201300255.
177. Molecular imaging of σ_1 receptors *In Vivo*: Current status and perspectives. P. Brust, W. Deuther-Conrad, K. Lehmkuhl, H. Jia, B. Wünsch, *Current Med. Chem.* **2014**, *21*, 35 - 69.

178. Involvement of apoptosis and autophagy in the death of RPMI 8226 multiple myeloma cells by two enantiomeric sigma receptor ligands.
K. Korpis, F. Weber, S. Brune, P. J. Bednarski, B. Wünsch, *Bioorg. Med. Chem.* **2014**, 22, 221 - 233. DOI 10.1016/j.bmc.2013.11.033.
179. Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist.
E. Falck, F. Begrow, E. Verspohl, B. Wünsch, *J. Pharm. Biomed. Anal.* **2014**, 88, 96 - 105. DOI 10.1016/j.jpba.2013.08.014.
180. Automation of the radiosynthesis and purification procedures for [¹⁸F]fluspidine preparation, a new radiotracer for clinical investigations in PET imaging of σ_1 receptors in brain.
A. Maisonal-Besset, U. Funke, B. Wenzel, S. Fischer, K. Holl, B. Wünsch, J. Steinbach, P. Brust, *Appl. Radiat. Isot.* **2014**, 84, 1 - 7. DOI 10.1016/j.apradiso.2013.10.015.
181. Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzuki-Miyaura cross-coupling.
A. Junker, D. Schepmann, J. Yamaguchi, K. Itami, A. Faust, K. Kopka, S. Wagner, B. Wünsch, *Org. Biomol. Chem.* **2014**, 12, 177 - 186. DOI 10.1039/C3OB41873A.
182. The sigma enigma: *In vitro/in silico* site-directed mutagenesis studies unveil σ_1 receptor ligand binding.
S. Brune, D. Schepmann, K.-H. Klempnauer, D. Marson, V. Dal Col, E. Laurini, M. Fermeglia, B. Wünsch, S. Prici, *Biochem.* **2014**, 53, 2993 - 3003. DOI 10.1021/bi401575g.
183. *In vitro* and *in vivo* biotransformation of WMS-1410, a potent GluN2B selective NMDA receptor antagonist.
E. Falck, F. Begrow, E. J. Verspohl, B. Wünsch, *J. Pharm. Biomed. Anal.* **2014**, 94, 36 - 44. DOI 10.1016/j.jpba.2014.01.017.
184. Synthesis, pharmacological evaluation, and σ_1 receptor interaction analysis of hydroxyethyl substituted piperazines.
F. Weber, S. Brune, K. Korpis, P. J. Bednarski, E. Laurini, V. Dal Col, S. Prici, D. Schepmann, B. Wünsch, *J. Med. Chem.* **2014**, 57, 2884 - 2894. DOI 10.1021/jm401707t.
185. Sharpless asymmetric dihydroxylation as key step in the enantioselective synthesis of spirocyclic σ_1 receptor ligands.
K. Holl, D. Schepmann, C. G. Daniliuc, B. Wünsch, *Tetrahedron: Asymmetry* **2014**, 25, 268 - 277. DOI 10.1016/j.tetasy.2013.12.009.
186. Cytotoxic activities of hydroxyethyl piperazine-based σ receptor ligands on cancer cells alone and in combination with melphalan, PB28 and haloperidol.
K. Korpis, F. Weber, B. Wünsch, P. J. Bednarski, *Pharmazie* **2014**, 69, 917 - 922. DOI 10.1691/ph.2014.4658.

187. Asymmetric synthesis of spirocyclic 2-benzopyrans for positron emission tomography of σ_1 receptors in the brain.
K. Holl, D. Schepmann, S. Fischer, F.-A. Ludwig, A. Hiller, C. K. Donat, W. Deuther-Conrad, P. Brust, B. Wünsch, *Pharmaceuticals* **2014**, *7*, 78 - 112. DOI 10.3390/ph7010078.
188. GluN2B-selective *N*-methyl-D-aspartate (NMDA) receptor antagonists derived from 3-benzazepines: Synthesis and pharmacological evaluation of benzo[7]annulen-7-amines.
A. Benner, A. Bonifazi, C. Shirataki, L. Temme, D. Schepmann, W. Quaglia, O. Shoji, Y. Watanabe, C. Daniliuc, B. Wünsch, *ChemMedChem* **2014**, *9*, 741 - 751. DOI 10.1002/cmdc.201300547.
189. Distinctive *In vivo* kinetics of the new sigma₁ receptor ligands (*R*)-(+)- and (*S*)-(-)-¹⁸F-fluspidine in porcine brain.
P. Brust, W. Deuther-Conrad, G. Becker, M. Patt, C. K. Donat, S. Stittsworth, S. Fischer, A. Hiller, B. Wenzel, S. Dukic-Stefanovic, S. Hesse, J. Steinbach, B. Wünsch, S. Z. Lever, O. Sabri, *J. Nucl. Med.* **2014**, *55*(10), 1730 - 1736. DOI 10.2967/jnumed.114.137562.
190. Bromolactamization: Key step in the stereoselective synthesis of enantiomerically pure, *cis*-configured perhydropyrroloquinoxalines.
A. Schulte, X. Situ, S. Saito, B. Wünsch, *Chirality* **2014**, *26*, 793 - 800. DOI 10.1002/chir.22350.
191. Synthesis, σ receptor affinity, and pharmacological evaluation of 5-Phenylsulfanyl and 5-benzyl-substituted tetrahydro-2-benzazepines.
P. Hasebein, B. Frehland, D. Schepmann, B. Wünsch, *ChemMedChem* **2014**, *9*, 1697 - 1703. DOI 10.1002/cmdc.201402110.
192. Synthesis and pharmacological evaluation of *like*- and *unlike*-configured tetrahydro-2-benzazepines with α -substituted benzyl moiety in 5-position.
P. Hasebein, B. Frehland, K. Lehmkuhl, R. Fröhlich, D. Schepmann, B. Wünsch, *Org. Biomol. Chem.* **2014**, *12*, 5407 - 5426. DOI 10.1039/c4ob00510d.
193. Combination of cyclohexane and piperazine based κ -opioid receptor agonists: Synthesis and pharmacological evaluation of *trans,trans*-configured perhydroquinoxalines.
C. Bourgeois, E. Werfel, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2014**, *22*, 3316 - 3324. DOI 10.1016/j.bmc.2014.04.054.
194. Pyridine analogues of spirocyclic σ_1 receptor ligands.
K. Miyata, G. Möller, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2014**, *22*, 4277 - 4284. DOI 10.1016/j.bmc.2014.05.033.

195. Stereoselective synthesis of *cis,cis*-configured vicinal triamines.
A. Schulte, S. Saito, B. Wünsch, *Eur. J. Org. Chem.* **2014**, 5749 - 5756.
DOI 10.1002/ejoc.201402685.
196. Synthesis and σ receptor affinity of regioisomeric spirocyclic furopyridines.
K. Miyata, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2014**, 83, 709 - 716.
DOI 10.1016/j.emech.2014.06.073.
197. Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ_1 receptor ligands.
E. Laurini, D. Harel, D. Marson, D. Schepmann, T. J. Schmidt, S. Pricl, B. Wünsch, *Eur. J. Med. Chem.* **2014**, 83, 526 - 533. DOI 10.1016/j.ejmech.2014.06.054.
198. Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ -opioid receptor agonists.
C. Bourgeois, E. Werfel, F. Galla, K. Lehmkuhl, H. Torres-Gómez, D. Schepmann, B. Kögel, T. Christoph, W. Straßburger, W. Englberger, M. Soeberdt, S. Hüwel, H.-J. Galla, B. Wünsch, *J. Med. Chem.* **2014**, 57, 6845 - 6860. DOI 10.1021/jm500940q.
199. Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
S. Gawaskar, D. Schepmann, A. Bonifazi, B. Wünsch, *Bioorg. Med. Chem.* **2014**, 22, 6638 - 6646. DOI 10.1016/j.bmc.2014.10.004.
200. Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands.
D. Zampieri, E. Laurini, L. Vio, M. Fermeglia, S. Pricl, B. Wünsch, D. Schepmann, M. G. Mamolo, *Eur. J. Med. Chem.* **2015**, 90, 797 - 808.
DOI 10.1016/j.ejmech.2014.12.018.
201. Selective and dual targeting of CCR2 and CCR5 receptors: A current overview.
A. Junker, A. K. Kokornaczyk, A. K. Strunz, B. Wünsch, in *Chemokines: Chemokines and their receptors in drug discovery*, editor N. Tschammer, series *Top. Med. Chem.* **2015**, 14, 187 - 242, Springer International Publishing, Berlin Heidelberg. DOI 10.1007/7355_2014_40.
202. A step forward in the sigma enigma: a role for chirality in the sigma1 receptor-ligand interaction?
D. Rossi, A. Marra, M. Rui, E. Laurini, M. Fermeglia, S. Pricl, D. Schepmann, B. Wünsch, M. Peviani, D. Curti, S. Collina, *MedChemComm* **2015**, 6, 138 - 146. DOI 10.1039/c4md00349g.

203. Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists.
A. Junker, A. K. Kokornaczyk, A. J. M. Zweemer, B. Frehland, D. Schepmann, J. Yamaguchi, K. Itami, A. Faust, S. Hermann, S. Wagner, M. Schäfers, M. Koch, C. Weiss, L. H. Heitman, K. Kopka, B. Wünsch, *Org. Biomol. Chem.* **2015**, *13*, 2407 - 2422. DOI 10.1039/c4ob02397h.
204. Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2).
A. K. Strunz, A. J. M. Zweemer, C. Weiss, D. Schepmann, A. Junker, L. H. Heitmann, M. Koch, B. Wünsch, *Bioorg. Med. Chem.* **2015**, *23*, 4034 - 4049. DOI 10.1016/j.bmc.2015.02.019.
205. Synthesis of hydrogenated 2-benzazepin-1-ones by the addition of aryllithium intermediates to isocyanates.
M. P. Quick, B. Wünsch, *Tetrahedron: Asymmetry* **2015**, *26*, 276 - 280. DOI 10.1016/j.tetasy.2015.01.018.
206. Novel potent N-methyl-D-aspartate (NMDA) receptor antagonists or σ_1 receptor ligands based on properly substituted 1,4-dioxane ring.
A. Bonifazi, F. Del Bello, V. Mammoli, A. Piergentili, R. Petrelli, C. Cimorelli, M. Pellei, D. Schepmann, B. Wünsch, E. Barocelli, S. Bertoni, L. Flammini, C. Amantini, M. Nabissi, G. Santoni, G. Vistoli, W. Quaglia, *J. Med. Chem.* **2015**, *58*, 8601 - 8615. DOI 10.1021/acs.jmedchem.5b01214.
207. Asymmetric synthesis of 3-substituted tetrahydro-2-benzazepines.
M. P. Quick, R. Fröhlich, D. Schepmann, B. Wünsch, *Org. Biomol. Chem.* **2015**, *13*, 7265 - 7281. DOI 10.1039/c5ob00731c.
208. Diastereoselective synthesis of cyclic five-membered *trans,trans*-configured nitrodiols by Double Henry Reaction of 1,4-dialdehydes.
J. Fröhlich, K. Lehmkuhl, R. Fröhlich, B. Wünsch, *Arch. Pharm. Chem. Life Sci.* **2015**, *348*, 589 - 594. DOI 10.1002/ardp.201500114.
209. Conformationally restricted κ -opioid receptor agonists: Synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines.
P. Molenveld, R. Bouzanne des Mazery, G. J. Sterk, R. P. M. Storcken, R. Autar, B. van Oss, R. N. S. van der Haas, R. Fröhlich, D. Schepmann, B. Wünsch, M. Soeberdt, *Bioorg. Med. Chem. Lett.* **2015**, *25*, 5326 - 5330. DOI 10.1016/j.bmcl.2015.09.040.

210. Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.
H. Torres-Gómez, K. Lehmkuhl, B. Frehland, C. Daniliuc, D. Schepmann, C. Ehrhardt, B. Wünsch, *Bioorg. Med. Chem.* **2015**, *23*, 4277 - 4285. DOI 10.1016/j.bmc.2016.06.030.
211. Quantitative analysis of DNA methylation in the promoter region of the methylguanine-O⁶-DNA-methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis.
S. Goedecke, J. Mühlisch, G. Hempel, M. C. Frühwald, B. Wünsch, *Electrophoresis* **2015**, *36*, 2939 - 2950. DOI 10.1002/elps.201500242.
212. Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: surprising effect of a nitro group in 2-position.
S. Gawaskar, D. Schepmann, A. Bonifazi, D. Robaa, W. Sippl, B. Wünsch, *Bioorg. Med. Chem. Lett.* **2015**, *25*, 5748 - 5751. DOI 10.1016/j.bmcl.2015.10.076.
213. Enantiomerically pure 2-methyltetrahydro-3-benzazepin-1-ols selectively blocking GluN2B subunit containing N-methyl-D-aspartate receptors.
B. Tewes, B. Frehland, D. Schepmann, D. Robaa, T. Uengwetwanit, F. Gaube, T. Winckler, W. Sippl, B. Wünsch, *J. Med. Chem.* **2015**, *58*, 6293 - 6305. DOI 10.1021/acs.jmedchem.5b00897.
214. Stereoselective synthesis of *cis,cis*-configured perhydroquinoxaline-5-carbonitrile from cyclohex-2-en-1-ol.
A. Schulte, S. Saito, B. Wünsch, *J. Heterocyclic Chem.* **2016**, *53*, 533 - 536. DOI 10.1002/jhet.2322.
215. Investigation of the Corey Bromolactamization with *N*-functionalized Allylamines.
A. Schulte, S. Janich, E.-U. Würthwein, S. Saito, B. Wünsch, *J. Heterocyclic Chem.* **2016**, *53*, 1827 - 1837. DOI 10.1002/jhet.2493.
216. Heck reaction as key step in the synthesis of hydrogenated 2-benzazepin-1-ones.
M. P. Quick, B. Wünsch, *J. Heterocyclic Chem.* **2016**, *53*, 1488 - 1493. DOI 10.1002/jhet.2452.
217. Effects of polar κ receptor agonists designed for the periphery on ATP-induced Ca²⁺ release from keratinocytes.
F. Galla, C. Bourgeois, K. Lehmkuhl, D. Schepmann, M. Soeberdt, T. Lotts, C. Abels, S. Ständer, B. Wünsch, *MedChemComm* **2016**, *7*, 317 - 326. DOI 10.1039/C5MD00414D.
218. Microwave-assisted regioselective direct C-H arylation of thiazole derivatives leading to increased σ_1 receptor affinity.
A. Kokornaczyk, D. Schepmann, J. Yamaguchi, K. Itami, B. Wünsch, *MedChemComm* **2016**, *7*, 327 - 331. DOI 10.1039/c5md00526d.

219. Novel GluN2B selective NMDA receptor antagonists: relative configuration of 7-methoxy-2-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ols.
B. Tewes, B. Frehland, R. Fröhlich, B. Wünsch, *Acta Cryst. Sect. E* **2016**, E72, 687 - 691. DOI 10.1107/S2056989016005843.
220. Crystal structure of (1S,2R)-7-benzyloxy-2-methyl-3-tosyl-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol: elucidation of the relative configuration of potent allosteric GluN2B selective NMDA receptor antagonists.
B. Tewes, B. Frehland, R. Fröhlich, B. Wünsch, *Acta Cryst. Sect. E* **2016**, E72, 683 - 686. DOI 10.1107/S2056989016005855.
221. Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.
I. Lüttnant, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2016**, 116, 136 - 146. DOI 10.1016/j.ejmech.2016.03.065.
222. Discovery of 2-(3,4-dichlorophenoxy)-N-(2-morpholin-4-ylethyl) acetamide: a selective σ_1 receptor ligand with antinociceptive effect.
G. Navarrete-Vázquez, A. Austrich-Olivares, B. Godínez-Chaparro, S. Hidalgo-Figueroa, S. Estrada-Soto, E. Hernández-Núñez, H. Torres-Gómez, D. Schepmann, B. Wünsch, *Biomed. Pharmacother.* **2016**, 79, 284 - 293. DOI 10.1016/j.biopha.2016.02.038.
223. Rigidity versus flexibility: is this an issue in σ_1 receptor ligand affinity and activity?
F. Weber, S. Brune, F. Börgel, C. Lange, K. Korpis, P. J. Bednarski, E. Laurini, M. Fermiglia, S. Pricl, D. Schepmann, B. Wünsch, *J. Med. Chem.* **2016**, 59, 5505 - 5519. DOI 10.1021/acs.jmedchem.6b00585.
224. Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold.
S. Dey, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem. Lett.* **2016**, 26, 889 - 893. DOI 10.1016/j.bmcl.2015.12.067.
225. Antinociceptive effects of a new sigma-1 receptor antagonist (N-(2-morpholin-4-ylethyl)-2-(1-naphthyloxy)acetamide) in two types of nociception.
B. A. García-Martínez, O. A. Jaramillo-Morales, J. V. Espinosa-Juárez, G. Navarrete-Vázquez, L. A. M. Hernández, J. R. Medina-López, A. M. Domínguez-Ramírez, D. Schepmann, B. Wünsch, F. J. López-Muñoz, *Eur. J. Pharmacol.* **2016**, 771, 10 - 17. DOI 10.1016/j.ejphar.2015.12.012.
226. 1st Joint European Conference on Therapeutic Targets and Medicinal Chemistry (TTMC 2015).
M. Le Borgne, S. Haidar, O. Duval, B. Wünsch, J. Jose, *Pharmaceuticals* **2016**, 9(1), 1. DOI 10.3390/ph9010001.

227. Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability.
V. Hugenberg, S. Hermann, F. Galla, M. Schäfers, B. Wünsch, H. C. Kolb, K. Szardenings, A. Lebedev, J. C. Walsh, V. P. Mocharla, U. B. Gangadharmath, K. Kopka, S. Wagner, *Nucl. Med. Biol.* **2016**, *43*, 424 - 437. DOI 10.1016/j.nucmedbio.2016.03.005.
228. Comparison of in silico, electrochemical, in vitro and in vivo metabolism of a homologous series of (radio)fluorinated σ_1 receptor ligands designed for positron emission tomography.
C. Wiese, E. Große Maestrup, F. Galla, D. Schepmann, A. Hiller, S. Fischer, F.-A. Ludwig, W. Deuther-Conrad, C. K. Donat, P. Brust, L. Büter, U. Karst, B. Wünsch, *ChemMedChem* **2016**, *11*, 2445 - 2458. DOI 10.1002/cmdc.201600366.
229. Oxa-Pictet-Spengler reaction as key step in the synthesis of novel σ receptor ligands with 2-benzopyran structure.
I. Knappmann, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2016**, *24*, 4045 - 4055. DOI 10.1016/j.bmc.2016.06.046.
230. Combinatorial effects of Doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
J. Stucke-Ring, J. Ronnacker, C. Brand, C. Höltke, C. Schliemann, T. Kessler, L. H. Schmidt, S. Harrach, V. Mantke, H. Hintelmann, W. Hartmann, E. Wardelmann, G. Lenz, B. Wünsch, C. Müller-Tidow, R. M. Mesters, C. Schwöppe, W. E. Berdel, *Oncotarget* **2016**, *7(50)*, 82458 - 82472. DOI: 10.18632/oncotarget.12559.
231. Synthesis of morphan derivatives with additional substituents in 8-position.
J. Stefanowitz, D. Schepmann, C. Daniliuc, S. Saito, B. Wünsch, *Z. Naturforsch.* **2016**, *71(10)*, 1057 - 1069. DOI 10.1515/znb-2016-0129.
232. Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.
D. Zampieri, L. Vio, M. Fermeiglia, S. Pricl, B. Wünsch, D. Schepmann, M. Romano, M. G. Mamolo, E. Laurini, *Eur. J. Med. Chem.* **2016**, *121*, 712 – 726, DOI 10.1016/j.ejmech.2016.06.001.
233. Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
M. Rui, D. Rossi, A. Marra, M. Paolillo, S. Schinelli, D. Curti, A. Tesei, M. Cortesi, A. Zamagni, E. Laurini, S. Pricl, D. Schepmann, B. Wünsch, E. Urban, V. Pace, S. Collina, *Eur. J. Med. Chem.* **2016**, *124*, 649 - 665. DOI 10.1016/j.ejmech.2016.08.067.
234. Synthesis and pharmacological evaluation of conformationally restricted κ -opioid receptor agonists.
Y. Wenker, M. Soeberdt, C. Daniliuc, S. Ständer, D. Schepmann, B. Wünsch, *MedChemComm* **2016**, *7*, 2368 - 2380. DOI 10.1039/C6MD00441E.

235. Evaluation of the enantiomer specific biokinetics and radiation doses of [¹⁸F]-fluspidine – a new tracer in clinical translation for imaging of σ_1 receptors.
M. Kranz, B. Sattler, N. Wüst, W. Deuther-Conrad, M. Patt, P. M. Meyer, S. Fischer, C. K. Donat, B. Wünsch, S. Hesse, J. Steinbach, P. Brust, O. Sabri, *Molecules* **2016**, *21*, 1164. DOI: 10.3390/molecules21091164.
236. Double intramolecular transacetalization of polyhydroxy acetals: Synthesis of conformationally-restricted 1,3-dioxanes with axially-oriented phenyl moiety.
S. Asare-Nkansah, B. Wünsch, *Molecules* **2016**, *21*, 1503. DOI 10.3390/molecules21111503.
237. Medicinal chemistry of σ_1 receptor ligands: Pharmacophore models, synthesis, structure affinity relationships and pharmacological applications.
F. Weber, B. Wünsch, *Chapter in: In: Kim F., Pasternak G. (eds) Sigma Proteins: Evolution of the Concept of Sigma Receptors. Handbook of Experimental Pharmacology, vol 244. Springer, Handb. Exp. Pharmacol.* **2017**, 51 - 79. DOI: 10.1007/164_2017_33.
238. Fluorinated PET tracers for molecular imaging of σ_1 receptors in the central nervous system.
F. Weber, P. Brust, E. Laurini, S. Pricl, B. Wünsch, Chapter in: Sigma Receptors: Their Role in Disease and as Therapeutic Targets, *Adv. Exp. Med. Biol.* **2017**, *964*, 31 - 48, Springer International Publishing, Berlin Heidelberg. DOI: 10.1007/978-3-319.
239. Gaining in pan-affinity towards sigma 1 and sigma 2 receptors. SAR studies on arylalkylamines.
D. Rossi, M. Rui, M. Di Giacomo, D. Schepmann, B. Wünsch, S. Monteleone, K. R. Liedl, S. Collina, *Bioorg. Med. Chem.* **2017**, *25*, 11 - 19. DOI 10.1016/j.bmc.2016.10.005.
240. Deconstruction – reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
S. Dey, L. Temme, J. A. Schreiber, D. Schepmann, B. Frehland, K. Lehmkuhl, N. Strutz-Seebohm, G. Seebohm, B. Wünsch, *Eur. J. Med. Chem.* **2017**, *138*, 552 - 564. DOI: 10.1016/j.ejmech.2017.06.068.
241. Systematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201.
S. L. Müller, J. A. Schreiber, D. Schepmann, N. Strutz-Seebohm, G. Seebohm, B. Wünsch, *Eur. J. Med. Chem.* **2017**, *129*, 124 - 134. DOI 10.1016/j.ejmech.2017.02.018.

242. Lipase-catalyzed kinetic resolution as key step in the synthesis of enantiomerically pure σ ligands with 2-benzopyran structure.
I. Knappmann, K. Lehmkuhl, J. Köhler, D. Schepmann, M. Giera, F. Bracher, B. Wünsch, *Bioorg. Med. Chem.* **2017**, *25*, 3384 - 3395. DOI: 10.1016/j.bmc.2017.04.042.
243. Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
Y. Shuto, S. Thum, L. Temme, D. Schepmann, M. Kitamura, B. Wünsch, *MedChemComm* **2017**, *8*, 975 - 981. DOI: 10.1039/c6md00621c.
244. Synthesis of conformationally restricted 1,3-dioxanes to analyze the bioactive conformation of 1,3-dioxane-based σ_1 and PCP receptor antagonists.
S. Asare-Nkansah, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2017**, *25*, 2472 - 2481. DOI: 10.1016/j.bmc.2017.03.014.
245. Der σ_1 -Rezeptor – das unbekannte Target.
F. Weber, B. Wünsch, *Pharm. Ztg.* **2017**, *162*, 338 - 344.
246. Design and synthesis of enantiomerically pure decahydroquinoxalines as potent and selective κ -opioid receptor agonists with anti-inflammatory activity *in vivo*.
M. Soeberdt, P. Molenveld, R. P. M. Storken, R. Bouzanne des Mazery, G. J. Sterk, R. Autar, M. G. Bolster, C. Wagner, S. N. H. Aerts, F. R. van Holst, A. Wegert, G. Tangherlini, B. Frehland, D. Schepmann, D. Metze, T. Lotts, U. Knie, K.-Y. Lin, T.-Y. Huang, C.-C. Lai, S. Ständer, B. Wünsch, C. Abels, *J. Med. Chem.* **2017**, *60*, 2526 - 2551. DOI: 10.1021/acs.jmedchem.6b01868.
247. PET imaging evaluation of four σ_1 radiotracers in nonhuman primates.
E. Baum, Z. Cai, F. Bois, D. Holden, S.-f. Lin, T. Lara-Jame, M. Kapinos, Y. Chen, W. Deuther-Conrad, S. Fischer, S. Dukic-Stefanovic, P. Bunse, B. Wünsch, P. Brust, H. Jia, Y. Huang, *J. Nucl. Med.* **2017**, *58*(6), 982 - 988. DOI: 10.2967/jnumed.116.188052.
248. Synthesis and evaluation of a [^{18}F]BODIPY-labeled caspase-inhibitor.
C. P. Ortmeyer, G. Haufe, K. Schwegmann, S. Herrmann, M. Schäfers, F. Börgel, B. Wünsch, S. Wagner, V. Hugenberg, *Bioorg. Med. Chem.* **2017**, *25*, 2167 - 2176. DOI: 10.1016/j.bmc.2017.02.033.
249. Stereoselective synthesis of conformationally restricted KOR agonists based on the 2,5-diazabicyclo[2.2.2]octane scaffold.
C. Wittig, D. Schepmann, M. Soeberdt, C. Daniliuc, B. Wünsch, *Org. Biomol. Chem.* **2017**, *15*, 6520 - 6540. DOI: 10.1039/C7OB01530E.

250. Thiazole-based σ_1 receptor ligands: Diversity by late-stage C-H arylation of thiazoles, structure-affinity and selectivity relationships, and molecular interactions.
A. K. Kokornaczyk, D. Schepmann, J. Yamaguchi, K. Itami, E. Laurini, M. Fermiglia, S. Pricl, B. Wünsch, *ChemMedChem* **2017**, *12*, 1070 - 1080. DOI: 10.1002/cmdc.201700166.
251. Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold.
S. Thum, A. K. Kokornaczyk, T. Seki, M. De Maria, N. V. Ortiz Zacarias, H. de Vries, C. Weiss, M. Koch, D. Schepmann, M. Kitamura, N. Tschammer, L. H. Heitmann, A. Junker, B. Wünsch, *Eur. J. Med. Chem.* **2017**, *135*, 401 - 413. DOI: 10.1016/j.ejmech.2017.04.046.
252. Molecular structure of a brominated 2-benzazepinone – a crucial intermediate in the synthesis of novel chemokine CCR2 receptor antagonists.
A. K. Kokornaczyk, S. Thum, C. G. Daniliuc, A. Junker, B. Wünsch, *Z. Naturforsch.* **2017**, *72(6)*, 421 - 424. DOI: 10.1515/znb-2017-0030.
253. Oxetanyl Amino Acids for Peptidomimetics.
G. P. Möller, S. Müller, B. T. Wolfstädter, S. Wolfrum, D. Schepmann, B. Wünsch, E. M. Carreira. *Org. Lett.* **2017**, *19*, 2510 - 2513. DOI: 10.1021/acs.orglett.7b00745.
254. Design, synthesis, pharmacological evaluation and docking studies of GluN2B-selective NMDA receptor antagonists with a benzo[7]annulen-7-amine scaffold.
S. Gawaskar, L. Temme, J. A. Schreiber, D. Schepmann, A. Bonifazi, D. Robaa, W. Sippl, N. Strutz-Seeböhm, G. Seeböhm, B. Wünsch, *ChemMedChem* **2017**, *12*, 1212 - 1222. DOI: 10.1002/cmdc.201700311.
255. Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ_1 receptor ligands.
L. Fanter, C. Müller, D. Schepmann, F. Bracher, B. Wünsch, *Bioorg. Med. Chem.* **2017**, *25*, 4778 - 4799. DOI: 10.1016/j.bmc.2017.07.027.
256. Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
S. Rath, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2017**, *25*, 5365 - 5372. DOI: 10.1016/j.bmc.2017.07.059.
257. Bioisosteric replacement of central 1,2,4-oxadiazole ring of high affinity CB₂ ligands by regioisomeric 1,3,4-oxadiazole ring.
D. Heimann, C. Lueg, H. de Vries, B. Frehland, D. Schepmann, L. H. Heitmann, B. Wünsch, *MedChemComm* **2017**, *8*, 1697 - 1705. DOI: 10.1039/c7md00296c.

258. NMDA-Rezeptoren – Seiltanz zwischen Gedächtnis und Demenz.
F. Weber, B. Wünsch, *Pharm. Ztg.* **2018**, *10*, 26 - 33.
259. A π -halogen bond of dibenzofuranones with the gatekeeper Phe113 in human protein kinase CK2 leads to potent tight binding inhibitors.
A. Schnitzler, A. Gratz, A. Bollacke, M. Weyrich, U. Kuckländer, B. Wünsch, C. Götz, K. Niefind, J. Jose, *Pharmaceuticals* **2018**, *11*, 23. DOI: 10.3390/ph11010023.
260. Evaluation of ^{11}C -Me-NB1 as a potential PET radioligand for measuring GluN2B-containing NMDA receptors, drug occupancy, and receptor crosstalk.
S. D. Krämer, T. Betzel, L. Mu, A. Haider, A. Müller Herde, A. K. Boninsegni, C. Keller, M. Szermerski, R. Schibli, B. Wünsch, S. M. Ametamey, *J. Nucl. Med.* **2018**, *59*(4), 698 - 703. DOI: 10.2967/jnumed.117.200451.
261. Solid-phase organic synthesis of chiral, non-racemic 1,2,4-trisubstituted 1,4-diazepanes with high σ_1 receptor affinity.
L. Fanter, D. Schepmann, B. Wünsch, *Arch. Pharm. Chem. Life Sci.* **2018**, 351:e1700334. DOI: 10.1002/ardp.201700334.
262. Optimization of the metabolic stability of a fluorinated cannabinoid receptor subtype 2 (CB₂) ligand designed for PET studies.
D. Heimann, F. Börgel, H. de Vries, M. Patberg, E. Jan-Smith, B. Frehland, D. Schepmann, L. H. Heitmann, B. Wünsch, *Eur. J. Med. Chem.* **2018**, *146*, 409 - 422. DOI: 10.1016/j.ejmech.2018.01.048.
263. Comparative pharmacological study of common NMDA receptor open channel blockers regarding their affinity and functional activity towards GluN2A and GluN2B NMDA receptors.
L. Temme, D. Schepmann, J. A. Schreiber, B. Frehland, B. Wünsch, *ChemMedChem* **2018**, *13*, 446 - 452. DOI: 10.1002/cmdc.201700810.
264. Synthesis of substituted 1-alkylidene-phthalanes via lithium-promoted 5-*exo-dig* cyclization.
P. Bunse, E.-U. Würthwein, B. Wünsch, *Eur. J. Org. Chem.* **2018**, 1806 - 1812. DOI: 10.1002/ejoc.201800205.
265. Optimization of pharmacokinetic properties by modification of a carbazole-based cannabinoid receptor subtype 2 (CB₂) ligand.
D. Heimann, F. Börgel, H. de Vries, K. Bachmann, V. E. Rose, B. Frehland, D. Schepmann, L. H. Heitmann, B. Wünsch, *Eur. J. Med. Chem.* **2018**, *143*, 1436 - 1447. DOI: 10.1016/j.ejmech.2017.10.049.

266. Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation.
L. Temme, B. Frehland, D. Schepmann, D. Robaa, W. Sippl, B. Wünsch, *Eur. J. Med. Chem.* **2018**, *144*, 672 - 681. DOI: 10.1016/j.ejmch.2017.12.054.
267. 2-Methyltetrahydro-3-benzazepin-1-ols – the missing link in SAR of GluN2B selective NMDA receptor antagonists.
S. Dey, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2018**, *26*, 501 - 508. DOI: 10.1016/j.bmc.2017.12.010.
268. Synthesis of 3-aza[4.4.3]propellanes with high σ_1 receptor affinity.
H. Torres-Gómez, C. Daniliuc, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2018**, *26*, 1705 - 1712. DOI: 10.1016/j.bmc.2018.02.019.
269. Fluorinated GluN2B receptor antagonists with a 3-benzazepine scaffold designed for PET studies.
M. Szermerski, F. Börgel, D. Schepmann, A. Haider, T. Betzel, S. Ametamey, B. Wünsch, *ChemMedChem* **2018**, *13*, 1058 - 1068. DOI: 10.1002/cmdc.201700819R1.
270. Synthesis of fluspidine via asymmetric NaBH_4 reduction of silicon enolates of β -keto esters.
S. Nakane, S. Yoshinaka, S. Iwase, Y. Shuto, P. Bunse, B. Wünsch, S. Tanaka, M. Kitamura, *Tetrahedron* **2018**, *74*, 5069 - 5084. DOI: 10.1016/j.tet.2018.04.005.
271. *In vitro* analyses of novel *HCN4* gene mutations.
M. Möller, N. Silbernagel, E. Wrobel, B. Stallmayer, E. Amedonu, S. Rinné, S. Peischar, S. G. Meuth, B. Wünsch, N. Strutz-Seebohm, N. Decher, E. Schulze-Bahr, G. Seebohm, *Cell. Physiol. Biochem. J.* **2018**, *49*, 1238 - 1248. DOI: 10.1159/000493301.
272. Design, (Radio)Synthesis, and in Vitro and in Vivo evaluation of highly selective and potent matrix metalloproteinase 12 (MMP-12) inhibitors as radiotracers for positron emission tomography.
V. Butsch, F. Börgel, F. Galla, K. Schwegmann, S. Hermann, M. Schäfers, B. Riemann, B. Wünsch, S. Wagner, *J. Med. Chem.* **2018**, *61*, 4115 - 4134. DOI: 10.1021/acs.jmedchem.8b00200.
273. Synthesis, receptor affinity, and antiallodynic activity of spirocyclic sigma receptor ligands with exocyclic amino moiety.
M. Bergkemper, E. Kronenberg, S. Thum, F. Börgel, C. Daniliuc, D. Schepmann, F. R. Nieto, P. Brust, R. F. Reinoso, I. Alvarez, B. Wünsch, *J. Med. Chem.* **2018**, *61*, 9666 - 9690. DOI: 10.1021/acs.jmedchem.8b01183.

274. Synthesis and pharmacological evaluation of enantiomerically pure GluN2B selective NMDA receptor antagonists.
F. Börgel, M. Szermerski, J. A. Schreiber, L. Temme, N. Strutz-Seeböhm, K. Lehmkuhl, D. Schepmann, S. M. Ametamey, G. Seeböhm, T. J. Schmidt, B. Wünsch, *ChemMedChem* **2018**, *13*, 1580 - 1587. DOI: 10.1002/cmdc.201800214.
275. Replacement of benzylpiperidine moiety with fluorinated phenylalkyl side chains for the development of GluN2B receptor ligands.
S. Thum, D. Schepmann, D. V. Kalinin, S. M. Ametamey, B. Wünsch, *ChemMedChem* **2018**, *13*, 2522 - 2529. DOI: 10.1002/cmdc.201800566.
276. Development of symmetric O-DOBIPYs with different optical properties as building blocks for the synthesis of ligands for multimodal imaging.
C. P. Konken, G. Haufe, K. Brömmel, B. Wünsch, M. Schäfers, S. Wagner, V. Hugenberg, *Dyes Pigm.* **2018**, *158*, 88 - 96. DOI: 10.1016/j.dyepig.2018.05.028.
277. Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold.
R. Zscherp, S. Baumeister, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2018**, *157*, 397 - 404. DOI: 10.1016/j.ejmech.2018.08.003.
278. Identification of dual sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.
M. Rui, G. Rossino, S. Coniglio, S. Monteleone, A. Scuteri, A. Malacrida, D. Rossi, L. Catenacci, M. Sorrenti, M. Paolillo, D. Curti, L. Venturini, D. Schepmann, B. Wünsch, K. R. Liedl, G. Cavaletti, V. Pace, E. Urban, S. Collina, *Eur. J. Med. Chem.* **2018**, *158*, 353 - 370. DOI: 10.1016/j.ejmech.2018.09.010.
279. Systematic variation of the benzoylhydrazine moiety of the GluN2A selective NMDA receptor antagonist TCN-201.
J. A. Schreiber, S. L. Müller, S. E. Westphälinger, D. Schepmann, N. Strutz-Seeböhm, G. Seeböhm, B. Wünsch, *Eur. J. Med. Chem.* **2018**, *158*, 259 - 269. DOI: 10.1016/j.ejmech.2018.09.006.
280. Stereochemistry of the Levy reaction.
L. Kröger, B. Wünsch, *Eur. J. Org. Chem.* **2018**, 6297 - 6303. DOI: 10.1002/ejoc.201801162.
281. Identification and preclinical evaluation of a radiofluorinated benzazepine derivative for imaging the GluN2B subunit of the ionotropic NMDA receptor.
A. Haider, I. Iten, H. Ahmed, A. Müller Herde, S. Gruber, S. D. Krämer, C. Keller, R. Schibli, B. Wünsch, L. Mu, S. M. Ametamey, *J. Nucl. Med.* **2019**, *60*, 259 - 266. DOI: 10.2967/jnumed.118.212134.

282. An assay to determine mechanisms of rapid autoantibody-induced neurotransmitter receptor endocytosis and vesicular trafficking in autoimmune encephalitis.
E. Amedonu, C. Brenker, S. Barman, J. A. Schreiber, S. Becker, S. Peischard, N. Strutz-Seebohm, C. Strippel, A. Dik, H.-P. Hartung, T. Budde, H. Wiendl, T. Strünker, B. Wünsch, N. Goebels, S. G. Meuth, G. Seebohm, N. Melzer, *Front. Neurol.* **2019**, *10*, Art. 178. DOI: 10.3389/fneur.2019.00178.
283. Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.
S. Baumeister, D. Schepmann, B. Wünsch, *MedChemComm* **2019**, *10*, 315 - 325. DOI: 10.1039/C8MD00545A.
284. Preclinical evaluation of benzazepine-based PET radioligands (R)- and (S)-¹¹C-Me-NB1 reveals distinct enantiomeric binding patterns and tightrope walk between GluN2B- and σ_1 -receptor-targeted PET imaging.
A. Haider, A. Müller Herde, S. D. Krämer, J. Varisco, C. Keller, K. Frauenknecht, Y. P. Auberson, L. Temme, D. Robaa, W. Sippl, R. Schibli, B. Wünsch, L. Mu, S. M. Ametamey, *J. Nucl. Med.* **2019**, *60*, 1167 - 1173. DOI: 10.2967/jnumed.118.221051.
285. Role of the NMDA receptor in the antitumor activity of chiral 1,4-dioxane ligands in MCF-7 and SKBR3 breast cancer cells.
M. B. Morelli, C. Amantini, M. Nabissi, G. Santoni, B. Wünsch, D. Schepmann, C. Cimarelli, M. Pellei, C. Santini, S. Fontana, V. Mammoli, W. Quaglia, A. Bonifazi, M. Giannella, G. Giorgioni, A. Piergentili, F. Del Bello, *ACS Med. Chem. Lett.* **2019**, *10*, 511 - 516. DOI: 10.1021/acsmchemlett.8b00536.
286. Development of novel quinoxaline-based κ -opioid receptor agonists for the treatment of neuroinflammation.
G. Tangherlini, D. V. Kalinin, D. Schepmann, T. Che, N. Mykicky, S. Ständer, K. Loser, B. Wünsch, *J. Med. Chem.* **2019**, *62*, 893 - 907. DOI: 10.1021/acs.jmedchem.8b01609.
287. Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold.
F. Börgel, F. Galla, K. Lehmkuhl, D. Schepmann, S. M. Ametamey, B. Wünsch, *J. Pharm. Biomed. Anal. A* **2019**, *172*, 214 - 222. DOI: 10.1016/j.jpba.2019.04.032.
288. Synthesis and structure-affinity relationships of spirocyclic benzopyrans with exocyclic amino moiety.
E. Kronenberg, F. Weber, S. Brune, D. Schepmann, C. Almansa, K. Friedland, E. Laurini, S. Priel, B. Wünsch, *J. Med. Chem.* **2019**, *62*, 4204 - 4217. DOI: 10.1021/acs.jmedchem.9b00449.

289. Structure-affinity relationships of 2,3,4,5-Tetrahydro-1*H*-3-benzazepine and 6,7,8,9-tetrahydro-5*H*-benzo[7]annulen-7-amine analogues and the discovery of a radiofluorinated 2,3,4,5-tetrahydro-1*H*-3-benzazepine congener for imaging GluN2B subunit-containing *N*-methyl-*D*-aspartate receptors.
H. Ahmed, A. Haider, J. Varisco, M. Stankovic, R. Wallimann, S. Gruber, I. Iten, A. Müller Herde, C. Keller, R. Schibli, D. Schepmann, L. Mu, B. Wünsch, S. M. Ametamey, *J. Med. Chem.* **2019**, *62*, 9450 - 9470. DOI: 10.1021/acs.jmedchem.9b00812.
290. Short and atom-economic enantioselective synthesis of the σ_1 -receptor ligands (S)- and (R)-fluspidine – important tools for positron emission tomography studies.
P. Bunse, C. Schlepforth, F. Glorius, M. Kitamura, B. Wünsch, *J. Org. Chem.* **2019**, *84*, 13744 - 13754. DOI: 10.1021/acs.joc.9b01882.
291. Synthesis and pharmacological evaluation of fluorinated benzo[7]annulen-7-amines as GluN2B-selective NMDA receptor antagonists.
S. Thum, D. Schepmann, R. F. Reinoso, I. Alvarez, S. M. Ametamey, B. Wünsch, *J. Labelled Compd. Radiopharm.* **2019**, *69*, 354 - 379. DOI: 10.1002/jlcr.3718.
292. *In vitro* and *in vivo* human metabolism of (S)-[¹⁸F]fluspidine – a radioligand for imaging σ_1 receptors with positron emission tomography (PET).
F.-A. Ludwig, S. Fischer, R. Houska, A. Hoepping, W. Deuther-Conrad, D. Schepmann, M. Patt, P. M. Meyer, S. Hesse, G.-A. Becker, F. R. Zientek, J. Steinbach, B. Wünsch, O. Sabri, P. Brust, *Front. Pharmacol.* **2019**, *10*, Art. 534. DOI: 10.3389/fphar.2019.00534.
293. Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists.
M. Wagner, D. Schepmann, S. M. Ametamey, B. Wünsch, *Bioorg. Med. Chem.* **2019**, *27* (16), 3559 - 3567. DOI: 10.1016/j.bmc.2019.06.035.
294. A common mechanism allows selective targeting of GluN2B subunit-containing *N*-methyl-*D*-aspartate receptors.
J. A. Schreiber, D. Schepmann, B. Frehland, S. Thum, M. Datunashvili, T. Budde, M. Hollmann, N. Strutz-Seebohm, B. Wünsch, G. Seebohm, *Commun. Biol.* **2019**, *2*, 420 - 433. DOI: 10.1038/s42003-019-0645-6.
295. Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ_1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity.
S. Thum, D. Schepmann, E. Ayet, M. Pujol, F. R. Nieto, S. M. Ametamey, B. Wünsch, *Eur. J. Med. Chem.* **2019**, *177*, 47 - 62. DOI: 10.1016/j.ejmech.2019.05.034
296. Structure-affinity relationships of fluorinated spirocyclic σ_2 receptor ligands with an exocyclic benzylamino moiety.
M. Bergkemper, E. Kronenberg, D. Schepmann, F.-A. Ludwig, P. Brust, B. Wünsch, *ChemMedChem* **2019**, *14*, 1392 - 1402. DOI: 10.1002/cmdc.201900284.

297. Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents.
D. Zampieri, S. Fortuna, A. Calabretti, M. Romano, R. Menegazzi, D. Schepmann, B. Wünsch, S. Collina, D. Zanon, M. G. Mamolo, *Eur. J. Med. Chem.* **2019**, *180*, 268 - 282. DOI: 10.1016/j.ejmech.2019.07.012.
298. Investigation of the role of chirality in the interaction with σ receptors and effect on binge eating episode of a potent σ_1 antagonist analogue of spipethiane.
F. Del Bello, M. V. M. Di Bonaventura, A. Bonifazi, B. Wünsch, D. Schepmann, J. B. Giancola, G. Vistoli, G. Giorgioni, W. Quaglia, A. Piergentili, C. Cifani, *J. Neurosci.* **2019**, *10*, 3391 - 3397. DOI: 10.1021/acschemneuro.9b00261.
299. Impact of hydroxy moieties at the benzo[7]annulene ring system of GluN2B ligands: Design, synthesis and biological evaluation.
L. Temme, F. Börgel, D. Schepmann, D. Robaa, W. Sippl, C. Daniliuc, B. Wünsch, *Bioorg. Med. Chem.* **2019**, *27* (23), 115146. DOI: 10.1016/j.bmc.2019.115146.
300. Pharmacological characterization of high-affinity σ_1 receptor ligands with spirocyclic thienopyran and hienzofuran scaffold.
D. Schepmann, C. Neue, S. Westphälinger, C. Müller, F. Bracher, C. Lange, P. Bednarski, C. Almansa, K. Friedland, V. Rübiger, M. Düfer, B. Wünsch, *J. Pharm. Pharmacol.* **2020**, *72*, 236 - 248. DOI: 10.1111/jphp.13196.
301. 4,4'-Diisothiocyanato-2,2'-stilbenedisulfonic acid (DIDS) modulates the activity of KCNQ1/KCNE1 channels by an interaction with the central pore region.
E. Bollmann, J. A. Schreiber, N. Ritter, S. Peischard, H. Tran Ho, B. Wünsch, T. Strünker, S. Meuth, T. Budde, N. Strutz-Seebohm, G. Seebohm, *Cell. Physiol. Biochem.* **2020**, *54*, 321 - 332. DOI: 10.33594/000000222.
302. New insights into the opening of the occluded ligand binding pocket of sigma1 receptor: binding of novel bivalent RC-33 derivative.
G. Rossino, I. Orellana, J. Caballero, D. Schepmann, B. Wünsch, M. Rui, D. Rossi, M. Gonzalez-Avendaño, S. Collina, *J. Chem. Inf. Model.* **2020**, *60*, 2, 756 - 765. DOI: 10.1021/acs.jcim.9b00649.
303. Structure – activity relationships of cinnamate ester analogs as potent antiprotozoal agents.
F. A. Bernal, M. Kaiser, B. Wünsch, T. J. Schmidt, *ChemMedChem.* **2020**, *15*, 68 - 78. DOI: 10.1002/cmdc.201900544.
304. Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
S. Baumeister, D. Schepmann, B. Wünsch, *Bioorg. Med. Chem.* **2020**, *28*(2), 115245. DOI: 10.1016/j.bmc.2019.115245.

305. Synthesis, Cytotoxicity Evaluation and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
D. Zampieri, S. Fortuna, A. Calabretti, M. Romano, R. Menegazzi, D. Schepmann, B. Wünsch, M. Mamolo, *ACS Med. Chem. Lett.* **2020**, *11*(5), 651 -656. DOI: 10.1021/acsmchemlett.9b00524.
306. Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds.
L. Temme, E. Bechthold, J. A. Schreiber, S. Gawaskar, D. Schepmann, D. Robaa, W. Sippl, G. Seebohm, B. Wünsch, *Eur. J. Med. Chem.* **2020**, *190*, 112138. DOI: 10.1016/j.ejmech.2020.112138.
307. Synthesis and SAR of tetracyclic inhibitors of protein kinase CK2 derived from furocarbazole W16.
L. Kröger, C. G. Daniliuc, D. Ensan, S. Borgert, C. Nienberg, M. Lauwers, M. Steinkrüger, J. Jose, M. Pietsch, B. Wünsch, *ChemMedChem* **2020**, *15*, 871 - 881. DOI: 10.1002/cmdc.202000040.
308. Design and synthesis of N-(benzylpiperidiny)-4-fluorobenzamide: a haloperidol analog that reduces neuropathic nociception via σ_1 receptor antagonism.
M. Déciga-Campos, L. A. Melo-Hernández, H. Torres-Gómez, B. Wünsch, D. Schepmann, M. E. González-Trujano, J. Espinoza-Juárez, F. J. López-Muñoz, G. Navarrete-Vázquez, *Life Sci.* **2020**, *245*, 117348. DOI: 10.1016/j.lfs.2020.117348.
309. Synthesis of small-molecule fluorescent probes for the in vitro imaging of calcium-activated potassium channel K_{Ca}3.1.
K. Brömmel, S. Maskri, I. Maisuls, C. P. Konken, M. Rieke, Z. Pethö, C. A. Strassert, O. Koch, A. Schwab, B. Wünsch, *Angew. Chem. Int. Ed.* **2020**, *59*, 8277 - 8284 and *Angew. Chem.* **2020**, *132*, 8354 - 8361. DOI: 10.1002/anie.202001201 and 10.1002/ange.202001201.
310. (\pm)-trans-2-phenyl-2,3-dihydrobenzofurans as leishmanicidal agents: synthesis, in vitro evaluation and SAR analysis.
F. A. Bernal, M. Gerhards, M. Kaiser, B. Wünsch, T. Schmidt, *Eur. J. Med. Chem.* **2020**, *205*, 112493. DOI: 10.1016/j.ejmech.2020.112493.
311. Sigma-1 receptor Positron Emission Tomography: A new molecular imaging approach using (S)-(-)-[¹⁸F]fluspidine in glioblastoma.
M. Toussaint, W. Deuther-Conrad, M. Kranz, S. Fischer, F.-A. Ludwig, T. A. Juratli, M. Patt, B. Wünsch, G. Schackert, O. Sabri, P. Brust, *Molecules* **2020**, *25*, 2170 - 2186. DOI: 10.3390/molecules25092170.

312. Synthesis and pharmacological evaluation of fluorinated quinoxaline-based κ -opioid receptor (KOR) agonists designed for PET studies.
G. Tangherlini, F. Börgel, D. Schepmann, S. Slocum, T. Che, S. Wagner, K. Schwegmann, S. Hermann, N. Mykicki, K. Loser, B. Wünsch, *ChemMedChem* **2020**, *15*, 1834 - 1853. DOI:10.1002/cmhc.202000502.
313. Enantiomerically pure quinoline-based κ -opioid receptor agonists: Chemoenzymatic synthesis and pharmacological evaluation.
B. Martin, D. Schepmann, F. A. Bernal, T. J. Schmidt, T. Che, K. Loser, B. Wünsch, *ChemMedChem* **2020**, *15*, 1408 - 1420. DOI: 10.1002/cmhc.202000300.
314. Rigid scaffolds: Synthesis of 2,6-bridged piperazines with functional groups in all three bridges.
D. Gao, C. Penno, B. Wünsch, *ChemistryOpen* **2020**, *9*, 874 - 889. DOI: 10.1002/open.202000188.
315. Co-staining of K_{Ca}3.1 channels in NSCLC cells with a small-molecule fluorescent probe and antibody-based indirect immunofluorescence.
K. Brömmel, S. Maskri, E. Bulk, Z. Pethö, M. Rieke, T. Budde, O. Koch, A. Schwab, B. Wünsch, *ChemMedChem* **2020**, *15*, 2462 - 2469. DOI: 10.1002/cmhc.202000652.
316. Fluorinated 2-Arylcyclopropan-1-amines – A new class of sigma receptor ligands.
B. Schinor, S. Hruschka, C. G. Daniliuc, D. Schepmann, B. Wünsch, G. Haufe, *Bioorg. Med. Chem.* **2020**, *28*, 115726. DOI: 10.1016/j.bmc.2020.115726.
317. Novel highly potent and selective sigma1 receptor antagonists effectively blocking the binge eating episode in female rats.
C. Cifani, E. Micioni Di Bonaventura, L. Botticelli, F. Del Bello, G. Giorgioni, P. Pavletic, A. Piergentili, W. Quaglia, A. Bonifazi, D. Schepmann, B. Wünsch, G. Vistoli, M. V. Micioni Di Bonaventura, *ACS Chem. Neurosci.* **2020**, *11*, 3107 - 3116. DOI: 10.1021/acscchemneuro.0c00456.
318. Setup and Validation of a reliable docking protocol for the development of neuroprotective agents by targeting the sigma-1 receptor (S1R).
G. Rossino, M. Rui, L. Pozzetti, D. Schepmann, B. Wünsch, D. Zampieri, G. Pellavio, U. Laforenza, S. Rinaldi, G. Colombo, L. Morelli, P. Linciano, D. Rossi, S. Collina, *Int. J. Mol. Sci.* **2020**, *21*(20), 7708. DOI: 10.3390/ijms21207708.
319. Neurodegenerative Erkrankungen: Wie Ifenprodil den Weg zu neuen Wirkstoffen weist.
F. Weber, J. Schreiber, B. Wünsch, *Dtsch. Apoth. Ztg.* **2020**, *48*, 64 - 68.

320. Synthesis of σ receptor ligands with a spirocyclic system connected with a tetrahydroisoquinoline moiety via different linkers.
M. Bergkemper, D. Schepmann, B. Wünsch, *ChemMedChem* **2021**, 16, 1184 - 1197. DOI: 10.1002/cmdc.202000861.
321. Discovery of a novel σ_1 receptor antagonist by combination of unbiased cell painting and thermal proteome profiling.
J. Wilke, T. Kawamura, H. Xu, A. Brause, A. Friese, M. Metz, D. Schepmann, B. Wünsch, A. Artacho-Cordón, F. R. Nieto, N. Watanabe, H. Osada, S. Ziegler, H. Waldmann, *Cell Chem. Biol.* **2021**, 848 - 854. DOI: 10.1016/j.chembiol.2021.01.009.
322. Selective inhibition of NMDA receptors with GluN2B subunit protects beta cells against stress-induced apoptotic cell death.
A. Gresch, H. Noguera Hurtado, L. Wörmeyer, V. Rübiger, R. Wiggers, G. Seebohm, B. Wünsch, M. Düfer, *J. Pharmacol. Exp. Ther.* **2021**, 379(3), 235 - 244. DOI: 10.1124/jpet.121.000807.
323. Deconstruction – reconstruction: Analysis of the crucial structural elements of GluN2B-selective, negative allosteric NMDA receptor modulators with 3-benzazepine scaffold.
N. Ritter, M. Korff, A. Markus, D. Schepmann, G. Seebohm, J. A. Schreiber, B. Wünsch, *Cell. Physiol. Biochem.* **2021**, 55(S3), 1-13. DOI: 10.33594/000000335.
324. Preclinical development of ^{18}F -OF-NB1 for imaging GluN2B-containing N-methyl-D-aspartate receptors and its utility as a biomarker for amyotrophic lateral sclerosis.
H. Ahmed, R. Wallimann, A. Haider, V. Hosseini, S. Gruber, M. Robledo, T. Nguyen, A. Müller Herde, I. Iten, C. Keller, V. Vogel, R. Schibli, B. Wünsch, L. Mu, S. M. Ametamey, *J. Nucl. Med.* **2021**, 62, 259 - 265. DOI: 10.2967/jnumed.120.246785.
325. Novel σ_1 antagonists designed for tumor therapy: structure - activity relationships of aminoethyl substituted cyclohexanes.
N. Kopp, C. Holtschulte, F. Börgel, K. Lehmkuhl, K. Friedland, G. Civenni, E. Laurini, C. V. Catapano, S. Pricl, H.-U. Humpf, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2021**, 210, 112950. DOI:10.1016/j.ejmech.2020.112950.
326. Synthesis of GluN2A-selective NMDA receptor antagonists with an electron-rich aromatic B-ring.
R. Rajan, D. Schepmann, J. A. Schreiber, G. Seebohm, B. Wünsch, *Eur. J. Med. Chem.* **2021**, 209, 112939. DOI: 10.1016/j.ejmech.2020.112939.

327. Synthesis and σ receptor affinity of spiro[[2]benzopyran-1,1'-cyclohexanes] with exocyclic amino moiety in 3'-position.
E. Kronenberg, F. Weber, D. Schepmann, B. Wünsch, *RSC Med. Chem.* **2021**, *12*, 237 - 244. DOI: 10.1039/d0md00307g.
328. Ifenprodil stereoisomers: Synthesis, absolute configuration and correlation with biological activity.
E. Bechthold, J. A. Schreiber, K. Lehmkuhl, B. Frehland, D. Schepmann, F. A. Bernal, C. Daniliuc, I. Álvarez, C. Val, T. J. Schmidt, G. Seebohm, B. Wünsch, *J. Med. Chem.* **2021**, *64*(2), 1170 - 1179. DOI: 10.1021/acs.jmedchem.0c01912.
329. Synthesis and biological evaluation of PET tracers designed for imaging of $K_{Ca3.1}$ channels in vivo.
K. Brömmel, C. P. Konken, F. Börgel, H. Obeng-Darko, S. Schelhaas, E. Bulk, T. Budde, A. Schwab, M. Schäfers, B. Wünsch, *RSC Adv.* **2021**, *11*, 30295 - 30304. DOI: 10.1039/D1RA03850H.
330. Synthesis and biological evaluation of natural product-inspired, aminoalkyl substituted 1-benzopyrans as novel antiplasmodial agents.
J.-F. Uth, F. Börgel, K. Lehmkuhl, D. Schepmann, M. Kaiser, V. A. P. Jabor, M. C. Nonato, R. L. Krauth-Siegel, T. J. Schmidt, B. Wünsch, *J. Med. Chem.* **2021**, *64*(9), 6397 - 6409. DOI: 10.1021/acs.jmedchem.1c00483.
331. Targeting $K_{Ca3.1}$ channels in cancer.
L. M. Todesca, S. Maskri, K. Brömmel, I. Thale, B. Wünsch, O. Koch, A. Schwab, *Cell. Physiol. Biochem.* **2021**, *55*(S3), 131 - 144. DOI: 10.33594/000000374.
332. Chemoenzymatic synthesis of 2,6-disubstituted tetrahydropyrans with high σ_1 receptor affinity, antitumor and analgesic activity.
N. Kopp, G. Civenni, D. Marson, E. Laurini, S. Pricl, C. V. Catapano, H.-U. Humpf, C. Almansa, F. R. Nieto, D. Schepmann, B. Wünsch, *Eur. J. Med. Chem.* **2021**, *219*, 113443. DOI: 10.1016/j.ejmech.2021.113443.
333. Diastereoselective synthesis of conformationally restricted KOR agonists.
D. Ilari, S. Maskri, D. Schepmann, J. Köhler, C. G. Daniliuc, O. Koch, B. Wünsch, *Org. Biomol. Chem.* **2021**, *19*, 4082 - 4099. DOI: 10.1039/d1ob00398d.
334. Propellanes as rigid scaffolds for the stereodefined attachment of σ -pharmacophoric structural elements to achieve σ affinity.
H. Torres-Gómez, C. Daniliuc, D. Schepmann, E. Laurini, S. Pricl, B. Wünsch, *Int. J. Mol. Sci.* **2021**, *22*, 5685 - 5728. DOI: 10.3390/ijms22115685.
335. Design, radiosynthesis and preliminary biological evaluation in mice of a brain-penetrant ^{18}F -labelled σ_2 receptor ligand.
R.-P. Moldovan, D. Gündel, R. Teodoro, F.-A. Ludwig, S. Fischer, M. Toussaint, D. Schepmann, B. Wünsch, P. Brust, W. Deuther-Conrad, *Int. J. Mol. Sci.* **2021**, *22*, 5447 - 5465. DOI: 10.3390/ijms22115447.

336. [2.2]Paracyclophane-based TCN-201 analogs as GluN2A-selective NMDA receptor antagonists.
R. Rajan, D. Schepmann, R. Steigerwald, J. A. Schreiber, E. El-Awaad, J. Jose, G. Seebohm, B. Wünsch, *ChemMedChem* **2021**, *16*(20), 3201 - 3209. DOI: 10.1002/cmdc.202100400.
337. Bitopic sigma 1 receptor modulators to shed light on molecular mechanisms underpinning ligand binding and receptor oligomerization.
G. Rossino, M. Rui, P. Linciano, D. Rossi, M. Boiocchi, M. Peviani, E. Poggio, D. Curti, D. Schepmann, B. Wünsch, M. Gonzales Avendano, A. Vergara-Jaque, J. Caballero, S. Collina, *J. Med. Chem.* **2021**, *64*, *20*, 14997 - 15016. DOI: 10.1021/acs.jmedchem.1c00886.
338. Synthesis and pharmacological evaluation of enantiomerically pure *endo*-configured KOR agonists with 2-azabicyclo[3.2.1]octane scaffold.
H. Jonas, D. Aiello, B. Frehland, K. Lehmkuhl, D. Schepmann, J. Köhler, P. Diana, B. Wünsch, *Org. Biomol. Chem.* **2021**, *19*, 8384 - 8396. DOI: 10.1039/D1OB01498F.
339. Can unlikely Neanderthal chloride channel CLC-2 gene variants provide insights in modern human infertility?
E. Jeworutzki, F. Tüttelmann, I. Rothenberg, M. Pusch, J. A. Schreiber, S. Kliesch, B. Wünsch, N. Strutz-Seebohm, G. Seebohm, *Cell. Physiol. Biochem.* **2021**, *55*, 301 - 310. DOI: 0.33594/000000376.
340. Quantitative structure-activity relationships of natural-product-inspired, aminoalkyl-substituted 1-benzopyrans as novel antiplasmodial agents.
F. M. Wunsch, B. Wünsch, F. A. Bernal, T. J. Schmidt, *Molecules*, **2021**, *26*, 5249. DOI: 10.3390/molecules26175249.
341. The action of reproductive fluids and contained steroids, prostaglandins, and Zn²⁺ on CatSper Ca²⁺ channels in human sperm.
J. K. Jeschke, C. Biagioni, T. Schierling, I. V. Wagner, F. Börgel, D. Schepmann, A. Schüring, A. E. Kulle, P. M. Holterhus, M. von Wolff, B. Wünsch, V. Nordhoff, T. Strünker, C. Brenker, *Front. Cell Dev. Biol.* **2021**, *9*, 699554. DOI: 10.3389/fcell.2021.699554.
342. A benzodiazepine activator locks Kv7.1 channels open by electro-mechanical uncoupling.
J. A. Schreiber, M. Möller, M. Zaydman, L. Zhao, Z. Beller, S. Becker, N. Ritter, P. Hou, J. Shi, J. Silva, E. Wrobel, N. Strutz-Seebohm, N. Decher, N. Schmitt, S. G. Meuth, M. Düfer, B. Wünsch, J. Cui, G. Seebohm, *Commun. Biol.* **2022**, *5*, 301. DOI: 10.1101/2021.02.11.430741.

343. K₂P18.1 translates T cell receptor signals into thymic 1 regulatory T cell development.
T. Ruck, S. Bock, S. Pfeuffer, C. B. Schroeter, D. Cengiz, P. Marziniak, M. Lindner, A. Herrmann, M. Liebmann, S. Kovac, L. Gola, L. Rolfes, M. Pawlitzki, N. Opel, T. Hahn, U. Dannlowski, T. Pap, F. Luessi, J. A. Schreiber, B. Wünsch, T. Kuhlmann, G. Seeböhm, B. Tackenberg, P. Seja, F. Döring, E. Wischmeyer, A. Imam Chasan, J. Roth, L. Klotz, G. Meyer zu Hörste, H. Wiendl, T. Marschall, S. Floess, J. Huehn, T. Budde, T. Bopp, S. Bittner, S. G. Meuth, *Cell Res.* **2022**, 32, 72 - 88. DOI: 10.1038/s41422-021-00580-z.
344. 2-(2-Hydroxyethyl)piperazine derivatives as potent human carbonic anhydrase inhibitors: synthesis, enzyme inhibition, computational studies and antiglaucoma activity.
N. Chiaramonte, A. Angeli, S. Sgambellone, A. Bonardi, A. Nocentini, G. Bartolucci, L. Braconi, S. Dei, L. Lucarini, E. Teodori, P. Gratteri, B. Wünsch, C. T. Supuran, M. N. Romanelli, *Eur. J. Med. Chem.* **2022**, 228, 114026. DOI: 10.1016/j.ejmech.2021.114026.
345. Synthesis of aminoethyl substituted piperidine derivatives with high σ_1 receptor affinity, selectivity and antiproliferative properties.
C. Holtschulte, F. Börgel, S. Westphäliger, D. Schepmann, G. Civenni, E. Laurini, D. Marson, C. V. Catapano, S. Pricl, B. Wünsch, *ChemMedChem* **2022**, 17, e202100735. DOI: 10.1002/cmcd.202100735.
346. Photocatalytic isomerization of (*E*)-anethole to (*Z*)-anethole.
M. Korff, T. O. Paulisch, F. Glorius, N. L. Doltsinis, B. Wünsch, *Molecules* **2022**, 27, 5342. DOI: 10.3390/molecules27165342.
347. Synthesis of tropane-based σ_1 receptor antagonists with antiallodynic activity.
E. Bechthold, J. A. Schreiber, N. Ritter, L. Grey, D. Schepmann, C. Daniliuc, R. González-Cano, F. R. Nieto, G. Seeböhm, B. Wünsch, *Eur. J. Med. Chem.* **2022**, 230, 114113. DOI: 10.1016/j.emech.2022.114113.
348. Synthesis of 8-aminomorphans with high KOR affinity.
H. Jonas, D. Aiello, D. Schepmann, P. Diana, B. Wünsch, *Eur. J. Med. Chem.* **2022**, 230, 114079. DOI: 10.1016/j.ejmech.2021.114079.
349. Synthesis of oxazolo-annulated 3-benzazepines designed by merging two negative allosteric NMDA receptor modulators.
A. Markus, D. Schepmann, B. Wünsch, *Arch. Pharm.* **2022**, 355(6), e2200020. DOI: 10.1002/ardp.202200020.

350. Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease.
B. Turgutalp, P. Bhattarai, T. Ercetin, R. Reis, C. Luise, E. E. Gurdal, A. Isaak, D. Biriken, E. Dinter, H. Sipahi, D. Schepmann, A. Junker, B. Wünsch, W. Sippl, H. Gulcan, C. Kizil, M. Yarim, *J. Med. Chem.* **2022**, *65(18)*, 12292 - 12318. DOI: 10.1021/acs.jmedchem.2c01003.
351. Synthesis and biological evaluation of conformationally restricted GluN2B ligands derived from eliprodil.
E. Bechthold, J. A. Schreiber, N. Ritter, D. Schepmann, C. Daniliuc, G. Seebohm, B. Wünsch, *Eur. J. Med. Chem.* **2022**, *237*, 114359. DOI: 10.1016/j.ejmech.2022.114359.
352. Phenol-benzoxazolone bioisosteres: Synthesis and biological evaluation of tricyclic GluN2B-selective *N*-methyl-D-aspartate receptor antagonists.
A. Markus, J. A. Schreiber, G. Goerges, B. Frehland, G. Seebohm, D. Schepmann, B. Wünsch, *Arch. Pharm.* **2022**, *355(9)*, e2200147. DOI: 10.1002/ardp.202200147.
353. Negative allosteric modulators of NMDA receptors with GluN2B subunit: Alanine-derived benoxazolone bioisosters of 2-methyl-3-benzazepine-1,7-diols.
A. Markus, B. Frehland, D. Schepmann, B. Wünsch, *Arch. Pharm.* **2022**, *355(9)*, e2200177. DOI: 10.1002/ardp.202200177.
354. Imaging of the calcium activated potassium channel 3.1 (K_{Ca}3.1) *in vivo* using a senicapoc-derived PET tracer.
C. P. Konken, K. Heßling, I. Thale, S. Schelhaas, J. Dabel, S. Maskri, E. Bulk, T. Budde, O. Koch, A. Schwab, M. Schäfers, B. Wünsch, *Arch. Pharm.* **2022**, *355*, e2200388. DOI: 10.1002/ardp.202200388.
355. Phenol-benzoxazolone bioisosteres of GluN2B-NMDA receptor antagonists: unexpected rearrangement during reductive alkylation with phenylcyclohexanone.
A. Markus, J. A. Schreiber, G. Goerges, B. Frehland, D. Schepmann, C. Daniliuc, R. Fröhlich, G. Seebohm, B. Wünsch, *Arch. Pharm.* **2022**, *355(11)*, e2200225. DOI: 10.1002/ardp.202200225.
356. Synthesis and antioxidative properties of 1,2,3,4-tetrahydropyridine derivatives with different substituents in 4-position.
D. Aiello, H. Jonas, A. Carbone, D. Carbone, C. Pecoraro, L. Tesoriere, J. Köhler, B. Wünsch, P. Diana, *Molecules* **2022**, *27*, 7423 - 7441. DOI: 10.3390/molecules27217423.
357. GluN2A-selective NMDA receptor antagonists: Mimicking the U-shaped bioactive conformation of TCN-201 by a [2.2]paracyclophane system.
R. Steigerwald, T.-H. Chou, H. Furukawa, B. Wünsch, *ChemMedChem* **2022**, *17*, e202200484. DOI: 10.1002/cmdc.202200484.

358. Imaging of K_{Ca}3.1 channels in tumor cells with PET and small-molecule fluorescent probes.
I. Thale, S. Maskri, L. Grey, L. M. Todesca, T. Budde, I. Maisuls, C. A. Strassert, O. Koch, A. Schwab, B. Wünsch, *ChemMedChem* **2022**, e202200551. DOI: 10.1002/cmdc.202200551.
359. Chemical, pharmacodynamic and pharmacokinetic characterization of the GluN2B receptor antagonist 3-(4-phenylbutyl),2,3,4,5-tetrahydro-1*H*-3-benzazepine-1,7-diol – starting point for PET tracer development.
M. Korff, R. Steigerwald, E. Bechthold, D. Schepmann, J. A. Schreiber, S. G. Meuth, G. Seebohm, B. Wünsch, *Biol. Chem.* **2023**, 404(4), 279-289. DOI: 10.1515/hsz-2022-0222.
360. In vitro ADME characterization of a very potent 3-acylamino-2-aminopropionic acid-derived GluN2C-NMDA receptor agonist and its ester prodrugs.
E. Bechthold, L. Grey, E. Diamant, J. Schmidt, R. Steigerwald, F. Zhao, K. B. Hansen, L. Bunch, R. P. Clausen, B. Wünsch, *Biol. Chem.* **2023**, 404(4), 255-265. DOI: 10.1515/hsz-2022-0229.
361. A novel NMDA Receptor-Test Model based on hiPSC-derived neural cells.
P. Disse, I. Aymanns, N. Ritter, S. Peischard, L. Korn, H. Wiendl, M. Pawlowski, S. Kovac, S. G. Meuth, T. Budde, N. Strutz-Seebohm, B. Wünsch, G. Seebohm, *Biol. Chem.* **2023**, 404(4), 267-277. DOI: 10.1515/hsz-2022-0216.
362. The second PI(3,5)P₂ binding site in the S0 helix of KCNQ1 stabilizes PIP₂-at the primary PI1 site with potential consequences on intermediate-to-open state transition.
M. Dellin, I. Rohrbeck, P. Asrani, J. A. Schreiber, N. Ritter, F. Glorius, B. Wünsch, T. Budde, L. Temme, T. Strünker, B. Stallmeyer, F. Tüttelmann, S. G. Meuth, M. Spehr, J. Matschke, A. Steinbicker, R. Stoll, N. Strutz-Seebohm, G. Seebohm, *Biol. Chem.* **2023**, 404(4), 241-254. DOI: 10.1515/hsz-2022-0247.
363. Validation of TREK1 ion channel activators as an immunomodulatory and neuroprotective strategy in neuroinflammation.
C. B. Schroeter, C. Nelke, M. Schewe, L. Spohler, A. M. Herrmann, T. Müntefering, N. Huntemann, M. Kuzikov, P. Gribbon, S. Albrecht, S. Bock, P. Hundehege, L. C. Neelsen, T. Baukrowitz, G. Seebohm, B. Wünsch, S. Bittner, T. Ruck, T. Budde, S. G. Meuth, *Biol. Chem.* **2023**, 404(4), 355-375. DOI: 10.1515/hsz-2022-0266.
364. Molecular mechanism of biased signaling at the kappa opioid receptor.
A. E. I. Daibani, J. M. Paggi, K. Kim, Y. D. Laloudakis, P. Popov, S. M. Bernhard, B. E. Krumm, R. H. J. Olsen, J. Diberto, F. I. Carroll, V. Katritch, B. Wünsch, R. O. Dror, T. Che, *Nature Commun.* **2023**, 14, 1338. DOI: 10.1038/s41467-023-37041-7.

365. Synthesis and functional characterization of novel RU1968-derived CatSper inhibitors with reduced stereochemical complexity.
T. Schierling, B. Tosi, C. Eisenhardt, S. Reining, C. Daniliuc, C. Brenker, T. Strünker, B. Wünsch, *ACS Pharmacol. Transl. Sci.* **2023**, *6*(1), 115 - 127. DOI: 10.1021/acsptsci.2c00188.
366. Downstream allosteric modulation of NMDA receptors by 3-benzazepine derivatives.
N. Ritter, P. Disse, I. Aymanns, L. Mücher, J. A. Schreiber, C. Brenker, T. Strünker, D. Schepmann, T. Budde, N. Strutz-Seebohm, S. M. Ametamey, B. Wünsch, G. Seebohm, *Mol. Neurobiol.* **2023**, *60*(12), 7238 -7252. DOI: 10.1007/s12035-023-03526-1.
367. Conformationally restricted σ_1 receptor antagonists from (-)-isopulegol.
L. Blicher, R. Gonzáles-Cano, E. Laurini, F. R. Nieto, J. Schmidt, D. Schepmann, S. Pricl, B. Wünsch, *J. Med. Chem.* **2023**, *66*(7), 4999 - 5020. DOI: 10.1021/acs.jmedchem.2c2081.
368. Chemical biology of ion channels (Chembion).
B. Wünsch, *Biol. Chem.* **2023**, *404*(4), 239 - 240. DOI: 10.1515/hsz-2023-0137.
369. Pharmacological potential of 3-benzazepines in NMDAR-linked pathophysiological processes.
N. Ritter, P. Disse, B. Wünsch, G. Seebohm, N. Strutz-Seebohm, *Biomedicines* **2023**, *11*(5), 1367. DOI: 10.3390/biomedicines11051367.
370. Discovery of RC-752, a novel sigma-1 receptor antagonist with antinociceptive activity: a promising tool for fighting neuropathic pain.
G. Rossino, A. Marra, R. Listro, M. Peviani, E. Poggio, D. Curti, G. Pellavio, U. Laforenza, G. Dondio, D. Schepmann, B. Wünsch, M. Bedeschi, N. Marino, A. Tesei, H.-J. Ha, Y. Ho Kim, J. Ann, J. Lee, P. Linciano, M. Di Giacomo, D. Rossi, S. Collina, *Pharmaceuticals* **2023**, *16*(7), 962. DOI: 10.3390/ph16070962.
371. Relationships between the structure of spiro[[2]benzopyran-1,1'-cyclohexan]-4'-amines and their σ_2 receptor affinity and selectivity.
E. Kronenberg, D. Schepmann, B. Wünsch, *Results Chem.* **2023**, *6*, 101057. DOI: 10.1016/j.rechem.2023.101057.
372. Indazole as phenol bioisostere: structure-affinity-relationships of GluN2B selective NMDA receptor antagonists.
J. Lücken, G. Goerges, N. Ritter, P. Disse, J. A. Schreiber, J. Schmidt, B. Frehland, D. Schepmann, G. Seebohm, B. Wünsch, *J. Med. Chem.* **2023**, *66*, 11573 – 11588. DOI: 10.1021/acs.jmedchem.3c01161.

373. Diastereoselective synthesis and structure-affinity relationships of σ_1 receptor ligands with spirocyclic scaffold.
T. Winge, D. Schepmann, J. Schmidt, C. Daniliuc, E.-U. Würthwein, B. Wünsch, *Org. Biomol. Chem.* **2023**, *21*, 7730. DOI: 10.1039/D3OB01169K.
374. Negative allosteric modulators of NMDA receptors with GluN2B subunit: synthesis of β -aminoalcohols by epoxide opening and subsequent rearrangement.
M. Korff, J. Lüken, J. Schmidt, D. Schepmann, G. Goerges, N. Ritter, P. Disse, J. A. Schreiber, G. Seebohm, B. Wünsch, *Org. Biomol. Chem.* **2023**, *21*, 7616 - 7638. DOI: 10.1039/D3OB01208E.
375. Synthesis and biological evaluation of enantiomerically pure (*R*)- and (*S*)-[^{18}F]OF-NB1 for imaging the GluN2B subunit-containing NMDA receptors.
M. Korff, A. Chaudhary, Y. Li, X. Zhou, C. Zhao, J. Rong, J. Chen, Z. Xiao, N. H. Elghazawy, W. Sippl, A. T. Davenport, J. B. Daunais, L. Wang, C. Abate, H. Ahmed, R. Crowe, T. J. Schmidt, S. H. Liang, S. M. Ametamey, B. Wünsch, A. Haider, *J. Med. Chem.* **2023**, *66*(23), 16018 – 16031. DOI: 10.1021/acs.jmedchem.3c01441.
376. Sigma Receptor and Aquaporin modulators: chiral resolution, configurational assignment, and preliminary biological profile of RC752 enantiomers.
R. Listro, A. Marra, V. Cavalloro, G. Rossino, P. Linciano, D. Rossi, E. Casali, M. De Amici, G. Mazzeo, g. Longhi, M. Fusè, G. Dondio, G. Pellavio, U. Laforenza, D. Schepmann, B. Wünsch, S. Collina, *J. Pharm. Biomed. Anal.* **2023**, *239*, 115902. DOI: 10.1016/j.jpba.2023.115902.
377. [^{18}F]Fluspidine – a PET tracer for imaging of σ_1 receptors in the central nervous system.
F. A. Ludwig, E. Laurini, J. Schmidt, S. Pricl, W. Deuther-Conrad, B. Wünsch, *Pharmaceuticals* **2024**, *17*, 166. DOI: 10.3390/ph17020166.
378. Late-stage diversification of pyrazoles as antileishmanial agents.
T. Winge, B. Perry, A. Matheussen, G. Caljon, B. Wünsch, *ChemMedChem* **2024**, e202400028. DOI: 10.1002/cmcd.202400028.

Patente

1. Lipasenmodulation.
J. Köhler, B. Wunsch
Deutsche Offenlegungsschrift DE 10 2005 029 115.5 A1, **2005**.
2. Spiro[benzopyran] or Spiro[benzofuran] derivatives which inhibit the sigma Receptor.
B. Wunsch, Laboratorios del Dr. Esteve, S.A.
PCT/EP2007/0035 54, 23.04.**2007**.
3. Pyrano-pyrazole-amines.
D. Schepmann, T. Schläger, D. Zamanillo-Castenedo, B. Wunsch
Europäische Patentanmeldung 07384022.5-1211, 16.04.**2007**.
4. Spiro-pyrano-pyrazole derivatives.
D. Schepmann, T. Schläger, D. Zamanillo-Castenedo, B. Wunsch
Europäische Patentanmeldung 07384021.7 - 1211, 16.04.**2007**.
5. Spiro [piperidine-4,4'-thieno [3, 2-C] pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis.
C. Oberdorf, D. Schepmann, B. Wunsch, D. Zamanillo-Castenedo
WO/2008/155132; 24.12.**2008**.
6. Perhydroquinoxaline derivatives as analgesics.
C. Bourgeois, D. Schepmann, B. Wunsch
Deutsche Patentanmeldung 10 2007 062 550.4, 20.12.**2007**,
PCT/EP2008/068000, 20.12.**2008**. WO/2009/080745; 02.07.**2009**.
7. Derivate benzanellierter Stickstoff-Heterocyclen.
P. Hasebein, D. Schepmann, B. Wunsch
Deutsche Patentanmeldung, 10 2008 035 596.8, 31.07.**2008**.
8. NR2B-selective NMDA-Receptor Antagonists.
B. Tewes, D. Schepmann, B. Wunsch
EP20090158697, 03.11.**2010**.
9. Pharmakologische Wirkstoffe und Radiodiagnostika mit ¹⁸F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung.
P. Brust, J. Steinbach, B. Wunsch
Deutsche Patentanmeldung, 10 2010 063974.5, 22.12.**2010**.
10. NR2B selective NMDA-Receptor Antagonists for treatment of immune-mediated inflammatory diseases.
B. Wunsch, D. Schepmann, S. Meuth, A. Bittner
Europäische Patentanmeldung Nr. 16 770 444.4, WO 2017/036880.
PCT/EP2016/069975. 31.08.2015. US 15/755,390 26.02.**2018**.

11. Benzazepin-1-ol-Derivate als PET-Liganden mit hoher in vivo NMDA-Spezifität.
S. Ametamey, B. Wunsch
US 2017/0224852 A1, 10.08.**2017**.
12. Azabicycloalkane und Verfahren zur Herstellung von Azabicycloalkanen.
L. Blicher, T. Schiedelko, D. Schepmann, B. Wunsch
UD 41822/SAM, 27.06.**2022**.
13. [¹⁸F]Fluspidine – a PET tracer for imaging of σ_1 receptors in the central nervous system.
F. A. Ludwig, E. Laurini, J. Schmidt, S. Prigl, W. Deuther-Conrad, B. Wunsch,
Pharmaceuticals **2024**, *17*, 166. DOI: 10.3390/ph17020166.

Übersichtsartikel

1. Relationships between the structure of dexoxadrol and etoxadrol analogues and their NMDA receptor affinity.
M. Sax, B. Wunsch, *Current Topics in Med. Chem.* **2006**, *6*, 723 - 732.
2. Reduction of carbonic and carboxylic acid derivatives.
B. Wunsch, C. Geiger, in *Houbel-Weyl, Science of Synthesis, 40a*, Georg Thieme Verlag, Stuttgart, **2009**, 23 - 64.
3. Hydroaminomethylation of alkenes.
A. Börner, M. Beller, B. Wunsch, in *Houbel-Weyl, Science of Synthesis, 40a*, Georg Thieme Verlag, Stuttgart, **2009**, 111 - 117.
4. Frontiers in medicinal chemistry 2010: The highlights
D. Schepmann, B. Wunsch, *ChemMedChem* **2010**, *5*, 949 - 954.
5. Pharmacophore models and development of spirocyclic ligands for σ_1 receptor.
B. Wunsch, *Curr. Pharm. Design* **2012**, *18*, 930 - 937. DOI 1873-4286/12.
6. The σ_1 receptor antagonist S1RA is a promising candidate for the treatment of neurogenic pain.
B. Wunsch, Viewpoint article *J. Med. Chem.* **2012**, *55*, 8209 - 8210. DOI 10.1021/jm3011993.
7. Structure of the σ_1 receptor and its ligand binding site.
S. Brune, S. Pricl, B. Wunsch, *J. Med. Chem.* **2013**, *56*, 9809 - 9819. DOI: 10.1021/jm400660u.
8. Molecular imaging of σ_1 receptors in vivo: Current status and perspectives.
P. Brust, W. Deuther-Conrad, K. Lehmkuhl, H. Jia, B. Wunsch, *Current Med. Chem.* **2014**, *21*, 35 - 69.
9. Selective and dual targeting of CCR2 and CCR5 receptors – a current overview.
A. Junker, A. K. Kokornaczyk, A. K. Strunz, B. Wunsch, in *Chemokines: Chemokines and their receptors in drug discovery*, editor N. Tschammer, series *Top. Med. Chem.* **2015**, *14*, 187 – 242, Springer International Publishing, Berlin Heidelberg. DOI 10.1007/7355_2014_40.
10. 1st Joint European Conference on Therapeutic Targets and Medicinal Chemistry (TTMC 2015).
M. Le Borgne, S. Haidar, O. Duval, B. Wunsch, J. Jose, *Pharmaceuticals* **2016**, *9(1)*, 1. DOI 10.3390/ph9010001.
11. Medicinal chemistry of σ_1 receptor ligands: Pharmacophore models, synthesis, structure affinity relationships and pharmacological applications.

F. Weber, B. Wünsch, *Chapter in: Sigma Receptors: Their role in Disease and as therapeutic targets. Handb. Exp. Pharmacol.* **2017**, 1 - 29. DOI: 10.1007/164_2017_33.

12. Fluorinated PET tracers for molecular imaging of σ_1 receptors in the central nervous system.
F. Weber, P. Brust, E. Laurini, S. Pricl, B. Wünsch, Chapter in: Sigma Receptors: Their Role in Disease and as Therapeutic Targets, *Adv. Exp. Med. Biol.* **2017**, 964, 31 - 48, Springer International Publishing, Berlin Heidelberg. DOI: 10.1007/978-3-319.
13. Der σ_1 -Rezeptor – das unbekannte Target.
F. Weber, B. Wünsch, *Pharm. Ztg.* **2017**, 162, 338 - 344.
14. Chemical biology of ion channels (Chembion).
B. Wünsch, *Biol. Chem.* **2023**. DOI: 10.1515/hsz-2023-0137.